Prostate Cancer Resistance to Cabazitaxel Chemotherapy by Begemann, Diane
University of Kentucky 
UKnowledge 
Theses and Dissertations--Toxicology and 
Cancer Biology Toxicology and Cancer Biology 
2020 
Prostate Cancer Resistance to Cabazitaxel Chemotherapy 
Diane Begemann 
University of Kentucky, diane.begemann@uky.edu 
Author ORCID Identifier: 
https://orcid.org/0000-0002-1742-4825 
Digital Object Identifier: https://doi.org/10.13023/etd.2020.187 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Begemann, Diane, "Prostate Cancer Resistance to Cabazitaxel Chemotherapy" (2020). Theses and 
Dissertations--Toxicology and Cancer Biology. 31. 
https://uknowledge.uky.edu/toxicology_etds/31 
This Doctoral Dissertation is brought to you for free and open access by the Toxicology and Cancer Biology at 
UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Toxicology and Cancer Biology by an 
authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my thesis or dissertation and abstract are my original work. Proper attribution 
has been given to all outside sources. I understand that I am solely responsible for obtaining 
any needed copyright permissions. I have obtained needed written permission statement(s) 
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing 
electronic distribution (if such use is not permitted by the fair use doctrine) which will be 
submitted to UKnowledge as Additional File. 
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and 
royalty-free license to archive and make accessible my work in whole or in part in all forms of 
media, now or hereafter known. I agree that the document mentioned above may be made 
available immediately for worldwide access unless an embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s thesis including all 
changes required by the advisory committee. The undersigned agree to abide by the statements 
above. 
Diane Begemann, Student 
Dr. Natasha Kyprianou, Major Professor 
Dr. Isabel Mellon, Director of Graduate Studies 
 
     
 
 
 
 
 
 
 
PROSTATE CANCER RESISTANCE TO CABAZITAXEL CHEMOTHERAPY 
 
 
 
 
________________________________________ 
 
DISSERTATION 
________________________________________ 
 
A dissertation submitted in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy in the 
College of Medicine 
at the University of Kentucky 
 
 
By 
Diane Begemann 
Lexington, Kentucky 
 
Co-Directors: Dr. Natasha Kyprianou,   
Professor of Urology,  Pathology and Oncological Sciences, 
Vice Chair of Basic Science Research, Department of Urology,  
Icahn School of Medicine at Mount Sinai 
New York, New York  
And Dr. John D’Orazio, Professor of Toxicology & Cancer Biology,  
University of Kentucky 
Lexington, Kentucky 
2020 
 
 
 
 
 
 
Copyright © Diane Begemann 2020 
[https://orcid.org/0000-0002-1742-4825]
 
     
 
 
 
 
 
 
 
ABSTRACT OF DISSERTATION 
 
 
 
 PROSTATE CANCER RESISTANCE TO CABAZITAXEL CHEMOTHERAPY 
 
 The plasticity of prostate tumors contributes to the heterogeneity in response and 
acquisition of therapeutic resistance in advanced prostate cancer. Disruption of the 
phenotypic landscape via epithelial-mesenchymal transition (EMT) enables prostate 
tumors to invade and metastasize. Our previous studies demonstrated that cabazitaxel (a 
2nd generation FDA-approved taxane chemotherapy) that is used for treatment of 
castration-resistant prostate cancer (CRPC), causes reversal of EMT to mesenchymal-
epithelial transition (MET). The present study examined the effect of sequencing 
cabazitaxel chemotherapy mediated MET on prostate tumor re-differentiation and its 
impact on overcoming resistance in models of advanced prostate cancer.   
The presence of DHT (1nM) decreases the efficacy of cabazitaxel treatment in 
vitro. Cabazitaxel treatment in vivo induced MET in LNCaP xenograft tumors as shown by 
increased E-cadherin and decreased N-cadherin expression. Sequencing cabazitaxel after 
ADT improves tumor response in androgen sensitive LNCaP models but not in CRPC 
22Rv1 models. In addition, a novel AR-HSET kinesin interaction is identified as a potential 
androgen receptor axis therapeutic target.   
Our findings provide new insights into re-programming prostate cells into an 
epithelial phenotype, towards re-sensitizing the cell to therapeutic targeting. There is high 
translational impact in therapeutic sequencing (cabazitaxel chemotherapy and ADT), an 
avenue towards improved therapeutic response in patients with advanced lethal CRPC.  
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1 
Chapter One: Introduction 
The Normal Prostate Gland 
 
The human prostate is a pyramidal-shaped endocrine organ located in the male 
pelvis beneath the bladder.  The prostate surrounds the urethra, and normally weighs 15-
20g (1).  The prostate is essential for the process of fertilization – it is responsible for 
secreting a fluid component of semen in ejaculation that protects and nourishes sperm (2).  
The organ is surrounded by a fibrous layer deemed the prostatic capsule or prostatic fascia, 
and fibromuscular tissue that contracts during ejaculation to expel prostatic fluid with 
sperm (1, 2).  Though it is one gland, there are three distinct histological zones – peripheral, 
transition, and central zones.  The peripheral zone comprises the posterior aspect of the 
gland and surrounds the distal urethra, and it is estimated that 70% of all prostate cancers 
develop in the peripheral zone (1).  In aging men, benign prostatic hyperplasia (BPH) is a 
frequent cause of lower urinary tract symptoms, and is defined by enlarged prostatic 
volume (>30mL) (3).  Approximately 50% of men over 50 years of age have pathological 
evidence of BPH (3). A summary of prostate anatomy, histology, and BPH is shown 
(Figure 1.1).  
During embryonic development the prostate develops from the endodermal 
urogenital sinus (UGS), which develops outgrowths that differentiate into prostatic 
glandular epithelium in response to fetal androgens (4).  The prostate remains a glandular 
organ, consisting of mostly pseudostratified epithelium but also containing areas of 
cuboidal, squamous, and transitional epithelium (5).  Prostatic acini and ductal epithelium 
consists of three types of cells: luminal, basal, and neuroendocrine (1).  Columnar luminal 
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cells secrete specialized products into the gland lumen, which contribute to seminal fluid 
– one of these products is prostate specific antigen (PSA), a protein that is measured in the 
blood for prostate cancer detection (6). The numerous ducts within the gland drain into 
canals, and then into 15-20 main ducts, which drain into the urethra (5).  Although the 
prostate is a glandular organ, there is a significant amount of prostatic stroma, a 
fibromuscular component containing smooth muscle, fibroblasts, blood vessels, and nerves 
that supports the epithelial cells with both physical infrastructure and through cell-cell 
signaling (7).    
In prostate development and normal function, androgens promote cell growth, 
survival, and differentiation (8, 9).  The principle male steroidal androgen, testosterone, is 
secreted from the testes and converted within the prostate epithelial cell by 5α-Reductase 
into its metabolite 5α-dihydrotestosterone (DHT) (9).  DHT has a high binding affinity for 
the androgen receptor (AR), which causes AR dimerization and binding to co-regulators, 
translocation to the nucleus where it acts as a transcription factor for target genes via 
binding to the androgen response element (ARE) (8, 9).  Multiple signaling cascades can 
result from this AR activity; increased free intracellular calcium, activation of protein 
kinase A (PKA), protein kinase C (PKC), and transcription of roughly 500 genes that 
promote growth and proliferation both in a normal prostate and as a critical pathway in the 
development of prostate cancer (9, 10).  
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Prostate Cancer  
 
Prostate cancer affects hundreds of thousands of men in the United States, with over 
174,000 new cases and over 31,000 estimated deaths for 2019 alone (11).  Prostate cancer 
has the highest number of new diagnoses in males, and is the second most lethal male 
cancer (11).  Over 75 years ago, in a ground breaking innovation, male steroid hormones 
were discovered to be involved in prostate cancer growth and proliferation (12).  Hormone 
withdrawal, or androgen deprivation therapy (ADT), was discovered to cause growth 
regression in prostate cancer by pioneer urologic surgeon-scientist Dr. Charles Huggins.  
However, for the majority of prostate cancer patients with androgen-dependent tumors, 
ADT is not curative, and disease regression/relapse after ADT is common (13-15). After 
ADT, emergence of tumors that are resistant are deemed castration resistant prostate cancer 
(CRPC), which can then develop into the worst clinical outcome for patients – metastatic 
castration resistant prostate cancer (mCRPC) (13-15). Unfortunately, the length of time 
before disease recurs after hormone therapy is variable and unpredictable, but can be as 
low as only several months (16).  
A patient at risk for prostate cancer risk is primarily monitored through prostate specific 
antigen (PSA) screening, a simple blood test, and a physical/digital rectal exam (DRE).  If 
a patient has a rising PSA after radiation treatment or surgery, the disease is termed 
biochemically recurrent. An estimated 50-65% of patients have biochemically recurrent 
disease (17) returning within a median of 18-24 months after ADT (18).  While local 
disease is highly curable with radical prostatectomy surgery,  robotic prostatectomy or 
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radiation therapy, those who progress to mCRPC have a median survival of less than two 
years and 90% will have metastasis to the bone (18). 
  Prostate epithelial cells undergo apoptosis in response to ADT treatment roughly 72 
hours after hormone withdrawal (19-21).  However, apoptosis occurs in only roughly 2-
3% of the total cell population alongside decreased proliferation in the majority of the cell 
population (21).  Apoptosis is the most studied cell death mechanism in response to 
hormone withdrawal, but ADT can also induce cellular senescence, and is linked with non-
programmed and non-specific cell death (necrosis) in a minority of cells (22).   
 
 
Cell Death Failures in Cancer Development 
 
Eukaryotic cells die via three modes: (1) apoptosis, programmed cell removal triggered 
by either internal cellular damage or an external signal; (2) anoikis, death induced by 
detachment from the extracellular matrix (ECM) and loss of contact from the 
microenvironment; and (3) necrosis, a non-specific process resulting in cell lysis and 
inflammation (23, 24).  Cancer cells have developed mechanisms to avoid programmed 
pathways anoikis and apoptosis, engaging in abnormal survival mechanisms to sustain their 
aberrant growth (23).  Evasion of apoptosis and emergence of anoikis resistance are critical 
mechanisms contributing to cancer initiation, metastasis and therapeutic resistance, thus 
rendering restoration of cell death mechanisms an attractive therapeutic platform for the 
treatment of advanced recurrent tumors (25-28). Overcoming apoptosis is essential for 
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initial tumor formation, acquisition of metastatic properties, and secondary site 
colonization (25, 29, 30) 
Mechanistically, there are two primary pathways to initiate apoptosisthe 
extrinsic/death-receptor (CD95 or FAS) pathway, and the intrinsic/mitochondrial pathway 
(31). Extrinsic apoptosis is activated by death-receptor ligand binding, such as FASL or 
TRAIL (Fas ligand and TNF Related Apoptosis Inducing Ligand, respectively) (23).  
Binding of these ligands induces receptor polymerization and subsequent activation of 
caspase-8 (26, 30). Caspase-8 triggers the activation of executioner caspases, such as 
caspase-3, 6, and 7, which carry out the apoptosis signaling cascade (32).  Intrinsic 
apoptosis begins through intracellular signals, such as mitochondrial or endoplasmic 
reticulum stress and DNA damage leading to apoptosome formation (cytochrome c, Apaf1, 
and caspase-9) and subsequent activation of executioner caspases 3, 6, and 7 (23).  
Extracellular signals can trigger the intrinsic pathway; for example lack of survival signals 
(e.g. growth factor withdrawal) can result to intrinsic pathway activation (33, 34).  In 
response to pro-apoptotic proteins like Bak and Bax (bcl-2 antagonist killer and bcl-2 like 
protein 4, respectively) are activated while anti-apoptotic proteins Bcl-2 and Bcl-xL are 
subdued (35, 36).  An increase in pro-apoptotic proteins bak/bax and decrease in anti-
apoptotic proteins Bcl-2/Bcl-xL cause cytochrome c release, apoptosome formation, 
caspase cascade activation and apoptosis (32, 37). 
Anoikis is the mode of apoptotic cell death  induced upon cell detachment from the 
ECM (25, 29). Normal epithelial and endothelial cells adhere to ECM, and die via anoikis, 
if ECM contact is lost. Mechanisms conferring resistance to anoikis facilitate the cancer 
cell dissemination, functionally contributing to metastasis and therapeutic resistance (30, 
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38).  Under conditions of normal homeostasis, detachment of epithelial or endothelial cells 
from the ECM leads to an increase of FAS and FASL, FAS polymerization and caspase-8 
activation, and ultimately anoikis induction (30).  ECM detachment directly causes 
increased Bak activity and decreased Bcl-xL activity, thus triggering apoptosis via the 
intrinsic pathway (36).  Anoikis resistant cells fail to activate caspase-8 after losing ECM 
anchoring, and engage Bcl-xL activity and consequently survive (30, 39). Normal cell-
ECM interactions are mediated through integrins, transmembrane proteins that are critical 
for cell attachment, survival, differentiation, migration and invasion (32).  Signal 
transduction from the extracellular environment to the intracellular network through the 
integrin network dictates anoikis resistance, cell invasion, and metastasis outcomes (34).  
Through aberrant integrin function, epithelial or endothelial cells can avoid anoikis by 
signal modifications including the integrins directly, downstream signaling effectors (37, 
38) or activation of survival pathways dependent on integrins (23, 33, 40, 41). 
AR signaling can induce anoikis through downregulation of p38, and ultimately 
suppress metastasis (42).  Intracellular reactive oxygen species in prostate cancer have been 
shown to activate pro-survival signals and anoikis resistance, with sensitivity to anoikis 
restored upon antioxidant treatment in prostate epithelial cells (43).   Chronic redox damage 
leads to Src activation regardless of cellular attachment, conferring anoikis resistance to 
highly damaged cells (43).  If detachment of cells from the prostate epithelium occurs, 
basal progenitor cells are stimulated to divide and differentiate into an epithelial phenotype 
to replace them (44). 
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Epithelial-Mesenchymal Transition (EMT) in Cancer Cell 
Dynamics 
 
Epithelial-mesenchymal transition (EMT) is a process through which an epithelial cell 
acquires migratory and invasive characteristics, and is a pivotal mechanism utilized by 
cells to escape their native microenvironment (35). Cells at the leading edge/periphery of 
tumors have undergone EMT, implicating the process in tumor development and expansion 
(45).  Epithelial cells are normally very cohesive, held together in a single layer via cell-
cell interactions  and navigated by cadherins, specifically E-Cadherin (46).  Adherence 
junctions are formed to connect stable epithelial cells, containing E-cadherin and other 
proteins such as β-catenin and actin to form stable junctions (46).  Through linking the 
cellular actin network to that of neighboring cells, adhering junctions effectively form a 
single, unified sheet from individual epithelial cells (46).  Loss of E-Cadherin expression 
and adhering junctions directly causes a loss in normal epithelial cell polarity and de-
differentiation into an amorphous cell without its anchor to other epithelial cells (Figure 
1.5). Upon EMT induction, adherence junctions disintegrate, releasing β-catenin from the 
junction into the cell cytosol, where it can translocate to the nucleus and act as a 
transcription factor (46); moreover other transcriptional regulators like E-Cadherin 
repressors snail and twist (46).  Epithelial cells have a distinct polarity, with proteins 
localized to either the apical or basolateral membrane surface. Membrane proteins claudin 
and occludin maintain these junctions, and are associated with cytosolic proteins such as 
Ankyrin to maintain polarity (47).  In order for epithelial cells to lose their polarity, these 
tight junctions must be dissolved.  
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The phenotypic landscape of EMT is  characterized by loss of epithelial markers (e.g. 
E-Cadherin, β-catenin, occludin) and a gain of mesenchymal markers (e.g. N-Cadherin, 
Zeb-1/2, vimentin, snail, twist) in addition to a loss of cell polarity (35).  Signaling 
pathways through extracellular receptors can trigger EMT reprogramming, such as platelet-
derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), 
transforming growth factor-β (TGF-β), and insulin-like growth factor-1 receptor (IGF-1R) 
(48).  Intracellular signaling pathways such as PI3K, Akt, and mTOR (48) can also navigate 
EMT outcomes. A key event in EMT induction is transcriptional regulation by primary 
transcription factors Snail, Slug, and Twist, which suppress expression of epithelial 
markers (E-cadherin) and upregulate corresponding mesenchymal proteins (N-cadherin) 
(48).   
Upon acquisition of the mesenchymal phenotype cells no longer need attachment 
for survival – therefore, cells that have undergone EMT do not die through anoikis but 
acquire freedom and survival, liberated from the “home” epithelial layer (47).  The key 
transcriptional regulators of EMT such as Slug and Snail confer anoikis resistance by 
targeting cell-cell adhesion molecules, as well as intracellular signaling effectors (25).  
Recent evidence supports the ability of E-cadherin to sensitize cells to anoikis, an intuitive 
role if the structural integrity of adhering junctions is disturbed (47).  Transcriptional 
repressors such as these silence downstream genes through epigenetic control (6).  Post-
translationally, E-cadherin can be degraded/cleaved or endocytosed under control of the 
GTPase Arf6 (6).  Consequential to EMT induction, E-cadherin transcription and 
expression are decreased.  Loss of E-cadherin has been shown to make cells resistant to 
anoikis, as demonstrated in E-cadherin knockout models, indicating that loss of an 
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epithelial phenotype is directly linked to loss of anoikis-mediated cell killing (47, 49).  E-
cadherin loss leads to a decrease in other proteins, such as β-catenin and Ankyrin-G. When 
not sequestered in adhering junctions with E-cadherin, β-catenin is released from the 
cytosol into the nucleus, acting as a transcription factor in control of genes regulating 
proliferation and migration.  While knockout of E-cadherin decreases anoikis, 
simultaneous loss of both E-cadherin and β-catenin restores sensitivity to anoikis, 
indicating that β-catenin is also a common control denominator between EMT and anoikis 
(47, 50).  Ankyrin-G, a protein that connects the cytoskeleton to the cell membrane, is also 
lost when cells undergo EMT and downregulate E-cadherin (47).  Loss of Ankyrin-G leads 
to reduced expression of p14ARF, a tumor suppressor that promotes anoikis – therefore, 
anoikis is also regulated through interactions between E-cadherin and Ankyrin-G (47), 
further implicating traditional EMT players as regulators of anoikis. The impact of 
interfacing EMT and anoikis in the tumor microenvironment landscape includes loss of 
cell-cell contact, acquisition of chemoresistance, immune escape (51), and metastatic 
spread (35).  In advanced disease, loss of E-cadherin expression correlates with higher 
Gleason score, the pathological scoring of prostate cancer on a scale of 1 (no cancer) to 5 
(widespread cancer) (36), extended local tumor progression, higher clinical stage, 
increased likelihood of metastasis and higher chance of biochemical recurrence after 
radical prostatectomy (52).  Thus an integrated EMT signature of the tumor landscape 
provides a unique biomarker value in prostate cancer progression.    
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Threading the Metastatic Journey of Cancer Cells 
 
In tumor progression, transitioning between a small, initial solid tumor into a 
metastatic cancer involves deregulation of several critical cellular processes. 
Neovascularization to the tumor has to occur before the tumor can exceed 2mm (24).  
Anoikis suppression by cancer cells promotes tumor neovascularization, making anoikis 
resistance not only mandatory for cell dissociation from its microenvironment, but also 
necessary for tumor expansion (24).  After volume expansion and the accumulation of 
mutations in the cancer cells, some cells manage to disassociate from and degrade the 
associated basement membrane/ECM and connective tissue, travel through ECM, and gain 
access to lymphatic or blood vessels (46).  Cancer cells must evade anoikis in order to 
continue surviving in circulation.  Anoikis evasion has been correlated with increasing 
numbers of prostate tumor circulating cells (CTC) (53), with the number of CTC correlated 
with poor prognosis, late disease recurrence and patient mortality, indicating the 
importance of anoikis evasion in disease progression (54, 55).  The combined effect of 
undergoing EMT and avoiding anoikis increases both cellular invasiveness and metastasis 
(56, 57) 
Anoikis resistance confers invasive properties in cancer cells, leading to metastasis, 
contributing to therapeutic resistance and ultimately impacting cancer patient mortality 
(58). The significance of anoikis evasion and activation of survival pathways as leading 
contributors to the emergence of CRPC has been established (27, 38, 59).  The Src-
navigated survival pathway whose activation is functionally linked the emergence of CRPC 
therapeutic resistance, leads to anoikis resistance via engaging the PI3K/Akt 
(phosphoinositide-3 kinase and protein kinase B, respectively) pathways (27).  Moreover, 
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loss of the PTEN tumor suppressor gene encoding for a protein that directly suppresses the 
PI3K/Akt pathway; loss of PTEN therefore increases PI3K/Akt activity, increases cell 
survival, and is common in poorly differentiated CRPC (28). In addition, overexpression 
of Bcl-2 and Bcl-xL results in apoptosis resistance, and is related to tumor survival after 
chemotherapy and radiotherapy (60).  A transcriptional repressor of E-cadherin, Snail, 
activates cell survival pathways such as PI3/Akt, inhibits executor caspase-3 antagonizes 
p-53 mediated apoptosis, in addition to downregulating E-cadherin (61).  Snail has been 
directly associated with chemoresistance (61).  Snail is activated by Notch1, a protein 
associated with EMT and commonly found in advanced tumors and recurring prostate 
cancer (62).  Twist, another transcriptional repressor, is associated with poor prognosis and 
the emergence of the mesenchymal phenotype (63) and can upregulate Bcl-2, enhancing 
survival and resistance to radiotherapy and chemotherapy (64, 65).  
Considering that extravasation has likely already occurred at the time of a patient’s 
diagnosis (66) renders preventative measures to impair tumor metastatic spread a 
challenge. Cells are either invading or dividing, but not both simultaneously (67); thus 
invasive cells are arrested in G1, capable of re-entering the cell cycle upon settling in a 
secondary location (67).  Circulating cells that have evaded anoikis are therefore not 
sensitive to classic chemotherapeutics, which target dividing cells, allowing the arrested 
cells to persist and seed secondary tumors (67, 68).  Phenotypic reversal of EMT to MET 
is temporally required in the colonizing tumor cells to retain their growth kinetics at the 
distant site of metastasis and confer a proliferative capacity with the cells return to a 
dividing phenotype and undergo mitosis (69).  
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EMT in the Tumor Microenvironment 
 
a. Transforming Growth Factor-β 
 
TGF-β (Transforming growth factor β) signals from the stroma and tumor 
microenvironment have a great effect on cancer cells (46, 63, 70).  TGF-β signaling in 
cancer is a complicated process, and can be simplified by understanding TGF-β as having 
a dual function.  In normal cells and initial stages of cancer, TGF-β acts as a tumor 
suppressor, but in later stages of cancer switches to a more classical growth factor and is 
associated with increased metastatic potential and worse patient prognosis (70).  A 
mechanism for this switch in TGF-β responses is not yet fully understood.  Excess TGF-β 
is correlated with rapid disease metastasis, and cancer metastases often contain higher 
TGF-β levels than the original seed/solid tumor (70).   
Metastatic cells from primary prostate tumors that have formed “quiescent micro-
metastatic deposits” in the secondary location of bone are stimulated to maintain their 
invasive characteristics through endogenous TGF-β signaling (46). These deposits of a 
single or a few cells can further develop into large metastases through continued EMT 
promotion (46).  Efforts to understand/define the contribution of TGF-β to EMT in the 
tumor microenvironment led to a link between high metastases occurrence and EMT of 
metastatic cells in the pre-metastatic niche (46, 63) (as illustrated on Figure 1.6). 
Mechanistically, TGF-β signaling begins with the TGF-β ligand binding a type II receptor 
(TβRII), which activates type I receptors (TβRI) and further initiating signal transduction 
through intracellular Smad2 and Smad3 phosphorylation (71).  Active/phosphorylated 
Smad2 and 3 translocate to the nucleus and form a complex with Smad4 (71).  The complex 
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of Smad 2, 3, and 4 acts as a transcription factor, recruits other cofactors, and increase the 
production of EMT transcription factors Snail, Twist, and Zeb1/2 (71).  Through this 
canonical Smad signaling, TGF-β is linked to EMT. In a non-canonical/Smad independent 
manner, TGF-β can determine EMT outcomes through downstream effectors MAP kinase 
and PI3K/Akt pathways (72). In addition to promoting EMT, TGF-β also regulates 
production of matrix metalloproteinases, enhancing the ability for cells undergoing EMT 
to migrate through the extracellular matrix as it is being digested by matrix 
metalloproteinases (63). TGF-β signaling also dictates the actin cytoskeleton remodeling 
by regulating cofilin expression and increasing filopodia formation and giving cells the 
ability to migrate and metastasize (62, 73).    
b. The Androgen Receptor (AR) Axis  
 
Activation of AR signaling in prostate epithelial cells occurs upon ligand binding 
and AR translocation to the nucleus where it functions as a transcription factor (Figure 1.2).  
However, in many cancers there is aberrant AR protein and signaling, with over 20 splicing 
mutations known (74).  AR can gain functional activity by diverse mechanisms including 
constitutive activation, ability to bind androgenic metabolites, and resistance to anti-
androgen therapy, via mutations in the ligand binding domain (74).  Microtubule-targeting 
taxane chemotherapy can also block AR translocation to the nucleus and therefore inhibit 
AR transcriptional activity regardless of the AR mutation load (74, 75).    
Dihydrotestosterone (DHT), the circulating form of androgen, suppresses of E-
cadherin expression through an increase in Snail (48).  However, this effect requires a 
threshold low level of AR, suggesting an inverse relationship between level of AR 
expression and degree of EMT induction through DHT/AR signaling (48).  A common 
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therapy could be promoting an aggressive phenotype through induction of EMT.  Work 
from this lab has shown that use of an AR antagonist such as abiraterone can negate the 
EMT changes induced by canonical androgen signaling and ADT (48).  By preventing 
EMT, AR antagonists function on more than one level as a treatment therapy; stopping 
androgen-dependent growth while also promoting an epithelial phenotype (48).  Androgen 
signaling linked to EMT contributes to high number of metastatic CRPC cases and there is 
a growing body of evidence supporting the involvement of EMT in the development of 
CRPC (48, 76, 77).  Low AR expression induced by ADT contributes to the aggressive 
nature of CRPC through inducing EMT, facilitating metastasis, and decreasing therapeutic 
efficacy (48, 77).  This evidence indicates that low AR signaling promotes prostate cancer, 
but it is also known that gain of function AR mutations and AR overexpression promote 
prostate cancer growth as well (48, 78).  Intermittent ADT, where androgen therapy is 
administered with scheduled gaps, is a treatment scheme designed to avoid AR 
downregulation and has provided some promise of improved clinical response to ADT 
(48).  Unfortunately, similar to what is seen with first generation ADT, many patients with 
CRPC become resistant to second generation antiandrogens enzalutamide and abiraterone.  
Resistance can develop through various mechanisms, including AR mutations, splice 
variants, constitutive activation, increased AR expression, or increased androgen synthesis 
from adrenal or intra-tumoral sources (78). Because several AR splice variants and mutants 
have altered C-terminal ligand binding domain, the un-mutated N-terminal domain has 
become a target of AR inhibition in recent research in order to treat the variants and mutants 
as effectively as the wild type AR (74). 
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AR Targeting Therapies  
 
In a subpopulation of prostate cancer patients, ADT leads to the emergence of 
castration resistant prostate cancer (CRPC) and the cancer no longer responds to ADT. 
Targeting androgen signaling and increased cell proliferation through a combination of 
anti-androgens and microtubule targeted chemotherapy has survival benefits for patients 
with metastatic CRPC (mCRPC), but therapeutic resistance can develop, resulting in lethal 
disease (79-82). Therapy resistance can result from the addiction of CRPC cells to 
androgen receptor (AR) signaling and constitutive activation of ligand independent AR 
splice variants (83).  
a.  Androgen Deprivation Therapy (ADT): Androgens have been 
defined as a growth factor for prostate gland growth and in prostate cancer since a seminal 
discovery by Huggins and Hodges (12).  Since that discovery, ADT in prostate cancer 
treatment has been targeting the AR signaling pathway (Figure 1.2).  More specifically, all 
clinically approved, existing endocrine targeting therapies in prostate cancer target the 
ligand binding domain (LBD) of the AR.     The original method of ADT was the removal 
of testicular androgens by orchiectomy surgery, introduced in late 1940s by the pioneering 
work of Dr Charles Huggins (12, 84, 85).  Patients were also treated with estrogens to block 
testicular androgens, but these patients experienced severe cardiovascular side effects (84).  
Shortly after the discovery of the androgen receptor, the first generation antiandrogen 
flutamide was discovered in 1967 and was later found to compete for AR binding and 
prevent its nuclear translocation (86).  Second generation antiandrogen, bicalutamide, was 
discovered in the 1980’s and has a four-fold greater binding affinity for AR binding than 
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its predecessor flutamide (86).  Luteinizing-hormone releasing hormone (LHRH) analogs 
were then developed, such as leuprolide (Lupron) and goserelin (Zoladex).  Systemic 
treatment with a LHRH analog/agonist results in GnRH receptor downregulation in the 
pituitary, which then results in a decrease of luteinizing-hormone (LH) and follicle 
stimulating hormone (FSH) production, followed by inhibition of testicular testosterone 
production (85).  Finasteride, the first type II 5α-Reductase inhibitor discovered, was 
initially used in patients with BPH to reduce testosterone conversion to DHT, and was 
found in the Prostate Cancer Prevention Trial to decrease risk of men developing prostate 
cancer (87, 88).  Finasteride is also used in patients to treat androgenic alopecia, working 
through reducing scalp DHT level and preventing hair loss (87).  Side effects of long term 
finasteride treatment include increased risk of urinary problems, sexual side effects, and a 
paradoxical increased risk of high-grade prostate cancer despite overall decreased risk of 
prostate cancer (88).          
b. Enzalutamide (MDV3100): The second generation antiandrogen 
flutamide was FDA approved in 1989, bicalutamide in 1995; then there was a lack of 
progress in AR inhibitors until third generation antiandrogen enzalutamide was discovered 
in 2008 and FDA approved in 2012 (86).    Enzalutamide is an AR antagonist that binds to 
the AR with a higher affinity than bicalutamide, preventing AR translocation to the 
nucleus, the recruitment of AR cofactors, and blocking AR binding to DNA (86, 89).  The 
AFFIRM Phase III, double blinded, placebo controlled clinical trial showed that 
enzalutamide had therapeutic benefit in metastatic castration-resistant prostate cancer 
patients that had previously been treated with taxanes (90, 91).  Enzalutamide-treated 
patients had PSA reduction, increased time to first skeletal related event, and an overall 
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survival of 18.4 months versus 13.6 months for placebo treated patients (91). In a direct 
comparison trial, patients that had been pre-treated with docetaxel had a worse response to 
enzalutamide than taxane-naïve patients, indicating that there may be a cross resistance 
mechanism occurring when docetaxel is given before enzalutamide, or that patients who 
progressed through docetaxel have disease that is less responsive to enzalutamide (92).       
Enzalutamide action puts a selective pressure on prostate cancer cells to restore 
androgen signaling and continue proliferating. AR-variants, such as AR-v7, and 
mutations, commonly the F876L point mutation, are common mechanisms of resistance 
to enzalutamide (93).  In addition, in an AR-independent mechanism of resistance, 
glucocorticoid receptor expression is increased in cells that are resistant to enzalutamide, 
found in both pre-clinical and clinical studies (93, 94).  Stimulation with glucocorticoid 
agonist dexamethasone is sufficient to confer enzalutamide resistance, while a 
glucocorticoid antagonist restores sensitivity (94).  Alarmingly, corticosteroids are 
routinely administered to patients undergoing docetaxel and abiraterone treatment to 
ameliorate side effects (94).  The chemical structure of enzalutamide is shown in Figure 
1.7.   
c. Abiraterone Acetate: Abiraterone, a novel anti-androgen therapy, was 
FDA approved in 2018 and targets adrenal androgen synthesis (95).  CYP17 is an enzyme 
critical in testosterone synthesis; through irreversible inhibition of CYP17, abiraterone 
blocks precursors for testosterone and DHT from being generated (95).  In an initial clinical 
trial on abiraterone, the COU-AA-301 randomized, double blinded, placebo controlled 
Phase II clinical trial in metastatic castration resistant prostate cancer patients, found that 
abiraterone provided a survival benefit of 4.6 months when compared to control (96, 97).  
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In patients who had already received enzalutamide alone or in combination with docetaxel, 
abiraterone was substantially less effective (98, 99).  Similar to enzalutamide, treatment 
with abiraterone can pressure cells to develop mutant or variant androgen receptors to 
maintain AR signaling for growth and proliferation.  The chemical structure of abiraterone 
is shown in Figure 1.7.   
d. N-terminal targeting, an approach for AR-variant inhibition: 
Structural changes in the AR, such as splice variants, are functional contributors to 
therapeutic resistance.  Many of the AR-variants have the ligand binding domain either 
mutated or deleted, located at the C-terminus of the AR (Figure 1.3) (83, 100).  Since most 
traditional anti-androgens bind the C-terminus, ADT does not work on AR-variants; it is 
also probable that the loss of the C-terminal domain is from selective pressure by C-
terminal targeting ADT (74, 100, 101).  Targeting the AR N-terminal domain (NTD) offers 
a broader AR population that can be effected by therapy, and this is the approach of the 
EPI small molecule inhibitors of the AR NTD (74, 101).  
A functional N-terminal domain is necessary for AR translocation to the nucleus, 
emphasizing the importance of a functional AR retaining a full length NTD (102).  EPI-
001 is a small molecule inhibitor of the AR N terminal domain, and prevents AR 
translocation to the nucleus through inhibiting protein-protein interactions necessary in the 
AR transcriptional complex such as CREB-binding protein and RAP74 (102-104). EPI-
001 effectively inhibits constitutively active AR splice variants that lack the ligand binding 
domain and are resistant to other ADT therapies (102).  EPI-001/002 in combination with 
docetaxel improves outcome in pre-clinical models of prostate cancer, decreases tumor 
growth, and increases apoptosis induction (74). In the same drug family, EPI-506 works in 
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the same manner of  AR NTD inhibition and is being investigated in phase I/II clinical 
trials for safety, dose, and efficacy in patients with prostate cancer (101).  Clinical trials 
are ongoing with the EPI drug family, with clinical potential for patients that express 
constitutively active AR-variants that are resistant to other AR targeting therapies.     
Contributions of Androgens to EMT  
 
The plasticity of fully differentiated prostate tumor glandular epithelium allows 
individual cells to de-differentiate into mesenchymal-like derivatives via the process of 
epithelial-mesenchymal transition (EMT) and re-differentiate via the reverse process, 
mesenchymal-epithelial transition (MET).  While EMT is a normal process in embryonic 
development (105), it can contribute to developing metastasis and advanced disease (106).  
EMT is characterized by a loss of epithelial cell markers (e.g. E-cadherin) and gain of 
mesenchymal cell markers (e.g. N-cadherin, vimentin) particularly at the invasive edge of 
a tumor (106).  Tumor cell EMT results from a set of transcriptional reprogramming, 
induced by signals from transforming growth factor-β (TGF-β), insulin-like growth factor-
1 receptor (IGF-1R), fibroblast growth factor receptor (FGFR), and platelet derived growth 
factor receptor (PDGFR) (107, 108). The androgen axis and TGF-β signaling intertwine in 
androgen-sensitive prostate cancer cells (109); moreover, prostate tumor cells undergo 
EMT more readily with a low AR content (59), indicating that there is multilayered 
complexity in the interaction between androgens and TGF-β towards EMT.  ADT has been 
shown to induce EMT in a sub-population of prostate cancer cells (110, 111), while our 
recent studies supported the impact of cabazitaxel to reverse EMT to MET (112).  
 
 
 
20 
Taxane Chemotherapy in Advanced Prostate Cancer: 
Stabilizing Microtubules  
 
Taxane chemotherapy is the standard of care for patients with metastatic CRPC 
who develop resistance to second generation anti-androgens such as abiraterone or 
enzalutamide (113, 114).  For over a decade, taxanes were the only class of Food and Drug 
Administration (FDA)-approved chemotherapeutic agents to confer additional survival and 
palliative benefit to CRPC patients (113, 114).  Second line taxane, cabazitaxel (Jevtana), 
was optimized from first line taxane chemotherapy (docetaxel, paclitaxel) for increased 
cellular retention due to its lower affinity for the p-glycoprotein efflux pump (114).  
Taxanes exert their primary antitumor action by stabilizing β-tubulin microtubule subunits, 
preventing microtubule depolymerization which induces G2-M arrest and apoptosis (Figure 
1.4) (113).  Taxanes pro-apoptotic effects are able to counteract Bcl-2 overexpression that 
is frequently observed in prostate cancer (115-118).  
Optimizing treatment with taxanes and ADT is a continual therapeutic challenge.  
Patients who have been treated with abiraterone have decreased response to docetaxel, 
indicating a cross-resistance between the two therapies in clinical settings (119). Preclinical 
evidence also shows evidence for cross resistance between AR targeting agents 
abiraterone, enzalutamide and taxane chemotherapy (120).  
a. Paclitaxel and Docetaxel: Paclitaxel was the first clinically available 
taxane, but was rapidly surpassed by docetaxel, a semisynthetic taxane that inhibits taxane 
de-polymerization approximately twice as effectively as paclitaxel in pre-clinical models 
(121). Clinical benefit for the use of docetaxel in patients with CRPC originated with a 
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series of clinical trials, TAX327 and SWOG-9916, which found a survival benefit of 
docetaxel (122).  Despite the fact that docetaxel is the first-line treatment for CRPC, 
response in some patients is limited and resistance develops (122, 123).  Surprisingly, PSA 
decrease is observed in only 45% of patients with CRPC when on docetaxel treatment 
(122).  In an effort to combat resistance to docetaxel, preclinical studies have tested the 
efficacy of giving small molecules that disrupt the anti-apoptotic reaction of Bcl-2/Bcl-xL 
with BAX/BAK (ABT-263 and ABT-737) and have found increased antitumor effects with 
combination treatment (123-125).     
Docetaxel was tested after ADT in the STAMPEDE trial in patients with non-
metastatic disease (31 men), and no benefit was determined by adding docetaxel after ADT 
(126).  A different STAMPEDE arm for patients with metastatic disease (550 men),  in 
which docetaxel therapy was given a median of 9 weeks after beginning ADT, showed a 
22% reduction in risk of all-cause death and a median of 10 months increased survival 
(126).  These STAMPEDE results indicate that docetaxel is effective in metastatic disease 
when given after ADT, but no benefit was found in non-metastatic disease.   
 Mutations in β-tubulin can occur, preventing taxane binding and altering 
microtubule monomer interactions (127).  Docetaxel has a high binding affinity for P-
Glycoprotein-1, an ATP-dependent drug efflux pump, thus increasing its movement out of 
the cell (128, 129).  Additionally, increased P-Glycoprotein-1 is observed throughout 
prostate cancer progression, an event that is either unrelated to docetaxel treatment but still 
aids in docetaxel resistance inadvertently, or an increase that develops in response to 
therapies (128, 129). The chemical structure of docetaxel is shown in Figure 1.7.   
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b. Cabazitaxel: The second line taxane chemotherapy cabazitaxel (Jevtana) 
has been shown to be effective in docetaxel-resistant CRPC patients (130, 131).  
Cabazitaxel is one of a very limited therapeutic options for patients who have failed 
docetaxel therapy and hormonal treatment (131).  Pre-clinical studies of cabazitaxel have 
shown that cabazitaxel stabilizes microtubules as effectively as docetaxel, but was 10-fold 
more potent than docetaxel in chemotherapy-resistant tumor cells (IC50 for docetaxel, 
0.17-4.01 µmol/L; cabazitaxel, 0.013-0.414 µmol/L) (114).  In cell lines resistant to 
docetaxel, cabazitaxel was still effective, indicating that it might be effective in clinical 
settings for patients with docetaxel resistant disease.  Cabazitaxel is taken up by the cells 
10 times faster than docetaxel; in addition, docetaxel has a half-life of 12 hours, while 
cabazitaxel is retained much longer and has a half-life in humans of 95 hours (132). Pre-
clinical results indicate that although cabazitaxel likely binds to microtubules at the same 
binding site as docetaxel, it stabilizes microtubules more strongly than docetaxel, is taken 
up more quickly, and is retained longer in the cell (132).  The chemical structure of 
cabazitaxel, with structural differences from docetaxel, is shown in Figure 1.7.   
In TROPIC, a randomized phase III clinical trial in men with mCRPC who had 
received previous hormone therapy and had progressed through docetaxel, cabazitaxel was 
found to increase median survival from 12.7 months to 15.1 months (133).  Cabazitaxel 
treated patients had a 30% relative reduction in risk of death, doubled rate of progression-
free survival, and showed PSA and tumor response (133).  Following this study, 
cabazitaxel was approved by the FDA in 2017 for use in docetaxel resistant CRPC patients.  
Published seven years after TROPIC, a different phase III trial, PROSELICA, investigated 
a lower dose of cabazitaxel (20mg/m2 compared to 25 mg/m2) in an effort to avoid severe 
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side effect symptoms for patients, and it was effective in decreasing treatment-emergent 
adverse effects, but secondary efficacy endpoints favored the higher dose of cabazitaxel 
(134). 
Microtubule Transport Proteins  
 
Microtubules are cytoskeletal polymeric structures present in all eukaryotic cells.  
Composed of repeating α/β tubulin heterodimers that alternate in a line to form a 
protofilament, 13 protofilaments align in parallel to form a hollow tube (135).  
Microtubules are extremely versatile, being about one hundred times stiffer than actin and 
intermediate filaments, but also flexible enough to bend laterally and grow in varied 
directions without breaking (135).    
Motor proteins are categorized into three super-families that exhibit directed 
movement on either microtubule or actin filaments.  The first are myosin motor proteins 
that move on actin filaments inside muscle cells, the second are dynein motor proteins that 
move on microtubules, and the third are kinesin motor proteins that also move on 
microtubules (136).  All three families utilize the energy from ATP to power the structural 
changes necessary for movement (136).  Kinesin and dynein motor proteins have been 
implicated in many signaling pathways involved in cancer progression (136).   
Kinesin-1 was the first molecular motor protein discovered to move cargo along 
microtubules (137).  There is a highly conserved, ~340 amino acid sequence shared by the 
majority of kinesin proteins that comprises the motor domain (138).  Though the motor 
domain is conserved, there is high variability between protein association and cargo-
binding domains that accounts for the high variability seen between individual kinesins 
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and their unique cellular function (138, 139).  Some kinesins have been found to regulate 
microtubule dynamics with no movement function at all, even though they possess the 
conserved motor protein domain (kinesin-13), while other kinesins both move along 
microtubules and modulate microtubule dynamics (kinesin-8) (136).  Kinesins move uni-
directionally, the majority towards the (+) end of microtubules, that is, away from the 
microtubule organizing center (MTOC) that is anchored in the centrosome (136, 140). 
However, the kinesin-C-terminal motor/kinesin-14 subfamily notably moves towards the 
(-) end of microtubules unlike the rest of the kinesin superfamily (141).   
a. KIFC1/HSET: KIFC1, also known as HSET, is one of the rare kinesin 
proteins that is a minus-end transporter, that is, moves towards the (-) end of microtubules 
(141, 142).  In mammalian cells, HSET is the only (-) directional, kinesin-14 family 
member (143).  HSET plays many critical roles in mitosis and meiosis (144).  Mitotic 
spindles change length rapidly when a cell is dividing, and HSET activity contributes to 
spindle length during cell division events (144).  HSET overexpression results in very long 
mitotic spindles, while HSET RNAi reduced the average length of microtubules (144).  In 
addition to manage spindle length in mitosis and meiosis, HSET is known to cross-link and 
slide microtubules as needed to increase microtubule length (144).  The normal function 
for HSET is in the nucleus; experiments that mutate the nuclear localization signal (NLS) 
of HSET result in cytoplasmic localization due to failure of nuclear import protein importin 
α/β to associate with the HSET NLS (144).  Work done with HSET-GFP fusion proteins 
reveals  nuclear localization under baseline conditions (144).  The function of HSET in 
spindle morphogenesis is dictated by a Ran gradient within the nucleus to aid in 
chromosomal alignment, microtubule cross linking, and successful cell division (144, 145).   
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HSET has been found to be overexpressed in a variety of cancer cells, and is 
positively correlated with both the stage and malignancy of a tumor (145).  In non-small 
cell lung cancer, HSET overexpression is associated with poor survival, and had 
dramatically increased expression when compared to paired normal tissue from the same 
patient (146).  In gastric cancer, HSET protein expression is up-regulated in 37% of cases, 
and in esophageal squamous cell carcinoma HSET is upregulated in cancer tissue when 
compared to neighboring non-plastic mucosa (147).  In breast cancer, HSET 
overexpression gives cells an inherent resistance to docetaxel chemotherapy (148).  In 
addition, HSET overexpression was found in docetaxel-resistant tumor samples, 
suggesting that HSET expression may play a role in response to taxane chemotherapy (148, 
149).  Previous work has shown that cabazitaxel treatment lowers HSET mRNA and 
protein expression in vitro (112), indicating that cabazitaxel may be an optimal therapeutic 
for patients that have a high HSET expression.  
b. KIF2C/MCAK: KIF2C, also known as mitotic centromere-associated 
kinesin (MCAK) is a member of the kinesin-13 subfamily, a non-motile kinesin that has a 
unique role within the cell of removing tubulin subunits from the microtubule end during 
mitotic progression (150-152).  In normal cells, MCAK is involved in kinetochore 
attachments to the centromere during mitosis (152, 153).  MCAK is regulated spatially by 
the Rac1-Aurora-A kinase pathway, which inhibits the microtubule depolymerizing 
activity of MCAK (154).  Through Aurora-A-mediated phosphorylation, MCAK is 
inhibited at the leading edge of motile cells, thereby allowing microtubules to grow within 
the cell towards the direction of movement (154).  MCAK promotes fast microtubule 
growth on a compliant 2D ECM surface, and slows microtubule growth on a compliant 3D 
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ECM surface (154).  In prostate tumors, MCAK expression increases with each disease 
stage from prostate adenocarcinoma, more so in hormone-sensitive prostate carcinoma, and 
even higher in CRPC in a dose-dependent pattern (153).  Because MCAK expression 
increases with increasing disease stage, there may be therapeutic potential for MCAK 
inhibition pending further investigative research (153).         
c.  Dynein motor proteins: Dyneins, like kinesins, motor in a unidirectional 
manner on microtubules to transport various cargo and organelles through the cell.  
However, dynein motor proteins move towards the (-) end of microtubules, that is moving 
towards the MTOC (136).  Unlike kinesins that move in a uniform 8nm step along one 
microtubule protofilament, dynein motors frequently step backwards and sideways around 
the surface of the microtubule (155-157).  Dynein motor proteins transport cargo, and are 
important in AR transport from the cytoplasm to the nucleus (158). Co-
immunoprecipitation analysis has shown AR-dynein intermediate chain association is 
increased upon R1881 (synthetic DHT) stimulation (158), indicating that the dynein motor 
protein is important in efficient AR transport from the cytoplasm into the nucleus under 
androgen stimulation.         
 
Taxanes Mechanisms of Action beyond Microtubule 
Stabilization  
 
Taxanes have many other effects on the cell aside from inducing mitotic arrest and 
apoptosis as a result of microtubule stabilization.  Forkhead box proteins comprise a family 
of transcription factors that are a direct downstream target of the PI3K/Akt pathway and 
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increase the transcription of a wide range of genes including those affectingcell cycle 
inhibition, apoptosis, DNA repair and defense from oxidative stress (159).  One forkhead 
box protein, FOXO1, is increased upon taxane treatment – this is critical in prostate cancer 
because FOXO1 is also a transcriptional repressor of AR (160). Through increasing a 
transcriptional repressor of AR, taxanes can decrease AR activity in a mechanism 
independent of androgen or endocrine signaling events (160).   Paclitaxel has been shown 
to induce apoptosis in breast and ovarian cancer cells via inducing FOXO1 nuclear 
localization, causing upregulation of the pro-apoptotic factor Bim (159-161).  FOXO3a, 
another forkhead box protein, is relocated into the nucleus upon paclitaxel treatment, a 
signaling event dependent on JNK and Akt signaling, and is likely a mediator in paclitaxel-
induced apoptosis (161).  FOXM1 is overexpressed in and correlated with docetaxel 
resistance in breast cancer, and gefitinib resistance in non-small cell lung cancer (162).  
FOXM1 is a critical protein in resistance to docetaxel and paclitaxel through regulating the 
microtubule destabilizing protein Stathmin and changing the microtubule dynamic, 
rendering the cell less responsive to the chemotherapeutic treatment (162).  Treatment with 
a FOXM1 inhibitor, thiostrepton, reverses taxane resistance, indicating a complicated, 
dynamic relationship between Forkhead box protein family and the efficacy of taxanes, 
and the potential for a combination treatment to optimize response to taxanes (162).    
Work from out lab provided the first evidence that taxane chemotherapy prevents 
AR translocation to the nucleus, resulting in AR cytoplasmic sequestration and inhibition 
of AR activity (Figure 1.4) (75).  In a tissue microarray of clinical specimens from 
docetaxel and untreated patients, AR immunohistochemistry revealed a dramatically 
different AR localization in specimens that were treated with docetaxel (75).  AR intensity 
 
 
 
28 
was not changed, but docetaxel treated patients had a 38% decrease in AR nuclear 
localization, bringing to light not only the importance of cellular localization for proper 
function but also novel effects of docetaxel treatment that is independent of mitotic arrest 
and apoptosis induction (75).  This effect has been confirmed by other groups in circulating 
tumor cells from docetaxel-treated patients that showed decreased nuclear localization of 
AR (158).  Further analysis into this effect revealed that the AR’s critical NTD is necessary 
for docetaxel to inhibit AR translocation, which provides therapeutic potential for 
preventing AR-variant translocation in addition to full length AR (75).   
Although taxanes are known for inducing apoptosis through microtubule 
stabilization and mitotic arrest, paclitaxel has also been shown to induce apoptosis through 
phosphorylation of the pro-survival protein Bcl-2 (163).  Mechanistically, the 
transcriptional repressor of E-cadherin, TWIST, has been shown to mediate paclitaxel 
resistance through the Akt and Bcl-2 pathways (164).  Bcl-2, as a functional mediator 
between taxane chemotherapy and apoptosis, with taxanes inducing a direct, pro-apoptotic 
effect on Bcl-2 but also Bcl-2 protecting the cell from taxane-induced-apoptosis (163, 164).  
This is confirmed when the combination of paclitaxel and ABT-263 (venetoclax), a Bcl-2 
inhibitor, increased therapeutic response to paclitaxel in vitro (165).  In sum, taxanes have 
many other effects within the cell that may be “off-target” for a microtubule stabilizing 
drug, but these additional effects contribute to apoptosis in a multi-faceted manner.     
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Targeted Therapeutics in Prostate Cancer 
 
Current therapeutic options for mCRPC are limited in efficacy and have high rates 
of therapeutic resistance. Options include androgen axis-targeting agents abiraterone and 
enzalutamide, microtubule stabilizing taxane chemotherapeutics cabazitaxel, radiotherapy 
Radium-223, and limited immunotherapy sipuleucel-T (78, 166).  A summary of the 
current therapeutics targeting cell death processes in prostate tumors is shown on Table 1.     
a. Kinesin Targeted Therapeutics: In vitro evidence indicated that HSET 
knockout cell lines have growth inhibition, reduced cell cycle kinetics, altered cell 
membrane, aneuploidy, and a disordered chromatin density (145).  HSET knockout cells 
have dramatically lower wound closure times, decreased colony formation, decreased 
spheroid formation, decreased cell proliferation, and disordered microtubule transport 
within the nucleus (145-147).  All of these factors come together and paint a favorable 
picture for HSET inhibition as an attractive therapeutic target for a variety of cancers.    
CW069, a novel HSET inhibitor, showed high selectivity for HSET in in vitro drug 
development, and decreases cell growth, centrosome clustering, centrosome amplification 
in cancer cells (167).  In pre-clinical models of prostate cancer, where HSET was 
discovered to induce docetaxel resistance (149), CW069 is effective in both docetaxel-
sensitive and resistant cell lines (168).  Promising work shows that CW069 sensitizes 
docetaxel-resistant prostate cancer cell lines to docetaxel treatment, indicating that there is 
potential clinical value in such a drug to be used in monotherapy or in combination with 
taxane chemotherapy (168).    
Early attempts to target MCAK via inhibitors have been done through kinesin 
spindle protein (KSP) inhibition, an approach that inhibits a wide range of kinesins 
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including MCAK and ten others (169).  MCAK was identified as a target of synthetic 
sulfoquinovosylacylglycerols (SQAGs), compounds with an 18 carbon long fatty acid 
chain on the glycerol moiety, after SQAGs were found to induce S and M phase arrest in 
cultured mammalian cells (170).  The other identified molecular target of SQAGs was 
DNA polymerase, and narrowing the cytotoxic effect to MCAK inhibition versus the effect 
of DNA polymerase inhibition complicates any beneficial results from SQAG treatment 
(170).    
b. Anoikis Inducing Agents: Quinazoline-based a1-adrenoreceptor 
antagonists such as Doxazosin and Terazosin have been previously shown to induce 
anoikis in urologic cancers (171).  Doxazosin has been heavily studied in prostate cancer 
and induces apoptosis by activating Caspase-3, which cleaves focal adhesion kinase (FAK) 
(172).  Active FAK suppresses anoikis, but cleaved FAK is non-functional and the cell 
undergoes anoikis (172).  Studies from our group on structural optimization of Doxazosin 
lead to the generation of a lead derivative, DZ-50, which exerts a potent anti-tumor effect 
via anoikis induction in both prostate and renal cancers (171, 173).  Induction of anoikis 
by DZ-50 was demonstrated by the loss of integrin-linked kinase and talin expression on 
prostate cancer lines PC3 and DU145 (49) leading to prostate tumor growth suppression 
and impairing metastasis in tumor models (49, 171).  In renal cell carcinoma, DZ-50 and 
doxazosin treatment resulted in significant suppression of migration and invasion while 
quinazoline derivatives exert antiangiogenic properties via anoikis, impairing tumor 
vascularity and growth (171).  Activation of p38 by Platycodin D activates p38 MAPK 
signaling and increases anoikis in other cancers (174). Another therapeutic approach for 
anoikis resistant metastatic renal cell carcinoma centers (mRCC) is based on the fact that 
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tyrosine receptor kinase B (TrkB) is commonly overexpressed in mRCC (175).  Treatment 
of mRCC tumors using the first line drug sorafenib leads to the emergence of resistance in 
cells overexpressing TrkB;  inhibiting TrkB sensitized cells to anoikis and sorafenib, with 
a therapeutic promise for anoikis-resistant tumors (176).   
c. EMT-MET Interconversions Rule the Microenvironment: First line 
treatment for patients with CRPC is to administer taxane chemotherapy, a microtubule 
targeting chemotherapeutic drug that functions by stabilizing microtubules and inducing 
apoptotic cell death (177), as well as impairing AR activity and interfering with EMT (59).  
The second generation taxane cabazitaxel, is clinically used only after patients have failed 
to respond to first generation taxanes treatment and hormonal therapy/second generation 
antiandrogens.  Recent work from our lab identified the ability of cabazitaxel to reverse 
EMT to mesenchymal-endothelial transition (MET) in both androgen-responsive and 
CRPC prostate cancer cells (177) indicating that the taxane mechanism of action extends 
beyond mitotic arrest and apoptosis. Interconversion of EMT to MET and subsequently 
inducing tumor re-differentiation through cabazitaxel treatment could be utilized to 
overcome therapeutic resistance to both AR-targeted and microtubule-targeting taxane 
therapies (177). Combination of ADT with taxane chemotherapy into a fashioned 
chemohormonal therapy  provides a therapeutic advantage to patients with advanced 
disease, compared to ADT alone (178) and calls for optimizing sequencing of the treatment 
regimens to increase survival. Recent optimization strategies include combination 
approaches of docetaxel with a Notch inhibitor to induce MET [88]. Inhibiting Notch 
causes deactivation of Snail, the transcriptional repressor of E-cadherin, thereby restoring 
transcription of E-cadherin, assisting the cancer cells in maintaining an endothelial 
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phenotype, metastatic cell reattachment, and promote MET (69). Selective targeting of the 
stromal cells in the tumor microenvironment has thus emerged as an attractive option for 
eradicating prostate cancer (179). Endothelial cells surrounding prostate tumors have been 
found to secrete growth factors such as IL-6 (180).  Phenotypic changes in the landscape 
of the prostate microenvironment after castration engage signaling through IL-6, AR 
downregulation, and associated upregulation of TGF-β, to promote tumor cell survival and 
invasiveness (181).  Blocking IL-6 signaling in co-cultured cancer epithelial cells and 
endothelial cells abrogated the effect of endothelial cells, enabling a new therapeutic 
platform (181).   
Further exploitation of EMT-MET interconversion within the tumor 
microenvironment enables development of new therapeutic platforms for targeted 
therapies against advanced tumors (63).  Local TGF-β signaling can induce distinct 
morphological changes in the tumor through the EMT regulators snail and twist (63).  
Inhibiting TGF-β signaling presented with clinical benefit in patients involved in ongoing 
clinical trials (182) and in our preclinical models of advanced prostate cancer (205). In the 
prostate microenvironment, androgens secreted in an autocrine/paracrine manner, rather 
than endocrine, enable androgen dependent tumor growth after ADT (182).  To combat 
this, the second generation antiandrogen, abiraterone is given because it inhibits androgens 
from both auto/paracrine and endocrine sources, including the adrenals  (182).   
d. Integrin-targeting agents:  Integrins are not only involved in cell-cell 
adhesion, but also navigate several signal transduction networks from the tumor 
microenvironment to intracellular signals (34), thus becoming attractive targets for cancer 
therapeutics. Specifically, the αvβ3 and αvβ5 integrins have a pharmacologic inhibitor 
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cilengitide, designed to antagonize integrin signaling and disrupt cell motility through the 
microenvironment (34). However, in a mCRPC phase II clinical trial reported in 2011, 
cilengitide treatment did not meet standards for patient improvement (183).  In this trial, 
the majority of patients had disease progression during drug treatment, hypothesized to be 
from cancer cells increasing integrin production and signaling in response to the drug 
treatment (183). Alternative integrin signaling-blocking therapies include monoclonal 
antibodies CNTO 95 and MEDI-522, in development for blocking integrin signaling in 
prostate cancer (184).  Despite disappointing clinical trials of cilengitide, the αvβ3 integrin 
has been found necessary for prostate cancer metastasis to the bone, supporting integrin 
signaling as an attractive drug target if more effective therapies can be designed (182).   
e.  Anti-angiogenic agents: Increased expression of vascular endothelial 
growth factor A (VEGFA) and platelet-derived growth factor β (PDGFβ) in tumors 
regulate local blood flow to dividing cells and target organs (48).  Sunitinib and sorafenib 
are two small-molecule tyrosine kinase inhibitors with potent anti-angiogenic properties 
via inhibiting VEGF receptor 2 and PDGF receptor β, depriving the tumor of signals that 
contribute to its survival (185).  Bevacizumab is a monoclonal antibody which binds and 
neutralizes VEGF (186), and has been in clinical use through phase II and III clinical trials 
for the treatment of advanced renal cell carcinoma (52).  Axitinib and pazopanib are newer 
anti-angiogenic drugs that work by inhibiting VEGFRs, causing decreased vascular 
growth, increased vascular permeability and tumor cell apoptosis (63, 70).  Still in clinical 
trials, anti-angiogenic drugs aflibercept and cediranib are being tested in combination 
therapy with prednisone and/or docetaxel for treatment of mCRPC (182).  The anoikis 
inducing agent DZ-50 was first demonstrated from this laboratory to impair  angiogenesis 
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through downregulation of the angiogenesis modulator thrombospondin 1, further 
increasing the translational potential of this novel attractive therapeutic (6, 176).   
f.  Inhibition of PI3K/Akt/mTOR Survival Pathway: mTOR is an 
evolutionarily conserved serine/threonine kinase downstream of the PI3K/Akt survival 
pathway that has been implicated in human cancers, including prostate cancer.  
Phosphorylation and aberrant activation of this pathway results in cell growth and 
proliferation without specific growth or survival signals, giving selective advantage to 
those cells and facilitating tumorigenesis (7).  The imidazo-quinoline derivative NVP-
BEZ235, a dual PI3K/mTOR inhibitor, shows antitumor activity against prostate tumors 
through limiting vasculature leakage in the tumor tissue microenvironment and reducing 
tumor interstitial fluid pressure effects (187-189).  NVP-BEZ235 is effective against 
prostate tumors regardless of PTEN status (188).  Combination treatment with Akt inhibitor 
MK-2206 and mTOR inhibitor MK-8669 (ridaforolimus) inhibits CRPC in a pre-clinical 
model (189-191).  The Akt inhibitor MK-2206 is currently undergoing clinical trials in 
non-urologic cancers as a combination therapy with initial promising results (192).   
g. Inhibition of TGF-β Signaling: TGF-β is a tumor suppressor in the early 
stages of prostate tumorigenesis, but a tumor promoter in advanced disease through 
multiple mechanisms (193, 194).  TGF-β research increased in 1990 after a seminal study 
showed that pre-treatment of adenocarcinoma cells with TGF-β1 in vitro increased 
tumorigenic and metastatic characteristics when injected into rats, characteristics attributed 
to increased matrix metalloproteases at the time (195).  TGF-β promotes tumorigenesis via 
induction of induction of EMT (196, 197).  If TGF-β signaling is blocked, such as through 
a dominant-negative TGF-β Receptor II (DN-TGFβRII) mutation, TGF-β signaling 
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becomes a potent tumor promoter and tumors are much more aggressive in pre-clinical 
models of prostate cancer, supporting the role of TGF-β as an early-stage tumor suppressor 
(198).  Dysfunctional TGF-β signaling in in vivo models accelerates malignant changes in 
the prostate through EMT induction, increased inflammation, increased proliferation, and 
significantly increased AR expression (198).  Clinically, TGFβRII mutations are more 
frequent than in the other TGF-β receptor, TGFβRI (199). Interestingly, DN-TGFβRII 
mutations increase TGF-β ligand mRNA expression, possibly through autocrine and 
paracrine feedback effects, where the increase in TGF-β ligand stimulate stromal cells and 
encourage angiogenesis, extracellular matrix degradation, and EMT, thus increasing tumor 
invasion and metastasis (198, 200).  
For patients with advanced prostate cancer, inhibiting TGF-β signaling is an 
attractive therapeutic target.  Galunisertib (LY2157299 monohydrate), a novel TGF-β 
receptor 1 (TGFBRI) inhibitor, is being investigated as monotherapy or in combination 
with standard therapies (201).  Galunisertib has been shown to inhibit TGF-β effector 
protein (SMAD) phosphorylation and activation alone and in the presence of free TGF-β 
ligand (202).  Galunisertib safety and efficacy has demonstrated in patients with 
hepatocellular carcinoma and glioblastoma (203, 204), and has been tested in pre-clinical 
models of prostate cancer (205).   
The use of galunisertib for patients with prostate cancer shows promise after pre-
clinical studies showed efficacy in combination therapy with enzalutamide (205).  
Treatment with galunisertib increased epithelial phenotype, indicating EMT to MET 
reversion, causing re-differentiation of prostate tumors, marked by increased cytokeratin-
18 expression (205).  Cofilin, a small protein regulator of actin cytoskeleton, decreased 
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with galunisertib treatment – the dramatic cofilin depletion compromises the integrity of 
the skeleton and may contribute to MET (73, 205).  Galunisertib had no effect on AR 
nuclear localization or intensity in a TRAMP mouse model, and did not decrease prostate 
tumor weight in monotherapy, but increased therapeutic response to enzalutamide in pre-
clinical models of advanced prostate cancer (205). TGF-β signaling in prostate cancer is a 
multi-faceted pathway with effects on the actin-cytoskeleton, cell phenotype, growth, 
invasion and metastatic ability.  Galunisertib provides a promising potential therapeutic for 
patients with advanced prostate cancer, bypassing AR signaling. The re-differentiation via 
MET also provides a therapeutic approach where galunisertib triggers a reversion to an 
epithelial phenotype, optimizing therapeutic response. 
h. Natural Therapeutic Agents: Research of natural compounds as an 
alternative or an addition to traditional therapeutics is increasing.  Extracts from the nettle 
leaf (Urtica Dioca) has been shown to increase caspase 3 and 9 mRNA levels, de-regulate 
apoptosis inhibitor Bcl-2, and inhibit proliferation in breast and prostate cancer cells in 
vitro (206).  Two compounds, punicalagin and ellagic acid, found in pomegranate peel 
extract (Punica Granatum), can inhibit growth by inducing apoptosis in prostate cancer 
cells in vitro through loss of mitochondrial transmembrane potential (207).  In addition, 
pomegranate peel extract inhibits proteins involved in metastasis through downregulation 
of matrix metalloproteinases MMP2 and MMP9, and upregulation of tissue inhibitor of 
metalloproteinase 2 (TIMP2) (207).  Pomegranate fruit extract also contains antitumor 
effects in mouse models through increase of pro-apoptotic Bax and Bak expression, 
corresponding downregulation of pro-survival Bcl-X, Bcl-2, cyclins D1, D2, E, cyclin 
dependent kinases cdk2, 4, and 6 in PC3 cells (208).  Outside of direct apoptosis inducers, 
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pomegranate fruit extract also decreased AR expression in a dose dependent manner in 
prostate cancer cell lines (208).  Pomegranate fruit extract administered in drinking water 
significantly decreased CWR22 prostate cancer tumor volumes, decreased serum PSA 
expression, and delayed tumor onset in a xenograft mouse model of prostate cancer (208).  
Terpenoids, a large class of natural compounds found in a wide range of fruit and 
vegetables, exhibit anti-oxidative and anti-inflammatory properties (209).  In breast and 
prostate cancer cells, terpenoids have been found to activate apoptosis through Bcl-2, NF-
κB and ubiquitin-proteasome inhibition (209).  It is notable that many of the terpenoids are 
not water soluble, which limits possible clinical application, and their pharmacokinetic 
characteristics have not yet been determined.        
Conclusions  
 
The therapeutic challenge in patients with advanced metastatic CRPC is to 
effectively increase survival more than a few months.  At the molecular level, the 
sequencing of therapeutic targeting to reverse EMT to MET and induce anoikis in 
metastatic cancer cells might be an emerging paradigm to be exploited. While EMT and 
resistance to anoikis are currently a therapeutic challenge, it is a characteristic that 
separates cancer cells from normally functioning cells, and any process that is unique to 
cancer cells can be exploited for therapeutic use.  Therapeutics that target EMT are in their 
infancy and need further development before a reliable, widely used therapeutic platform 
is constructed.  EMT programming can bypass the cell’s ability to die upon detachment, 
causing a temporal interconversion of its phenotype extending survival, enter the 
bloodstream, metastasize, invade secondary tissues, and successfully colonize in the distant 
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site.  The clinical benefits of exploiting the anoikis-EMT connection is prevention of 
metastasis before it can begin while overcoming therapy resistance. Recent advances in 
molecular profiling of prostate tumor landscape have defined several molecular signatures 
based on dissection of significant processes operational in prostate cancer cells. How can 
a therapeutic window in these temporal events then be capturing a subset of tumor 
epithelial cells ready to be targeted after the anoikis resistance offense is down regulated 
by the EMT effectors?  Prostate cancer is one of the most lethal male cancers in the US 
today, but restoration of anoikis sensitivity and a reprogramming of EMT towards cell 
execution will aid in overcoming therapeutic resistance and increasing survival.   
Inhibiting anoikis and related cellular events including EMT, increased motility and 
chemoresistance would restore a sort of neutrality to the tumor through prevention of 
disease spread.  To block extravasation would mean blocking metastatic events before they 
can begin and keep disease states in a realm where therapies are more effective – treating 
the primary tumor rather than advanced disease.  When metastatic events occur, almost all 
therapeutic regimes universally fail.  The “holy grail” of effectively treating metastatic 
disease might be to prevent the metastic journey and cell colonization from occurring in 
the first place by overcoming resistance to anoikis via sensitizing the cells to EMT-MET 
reversal and acquisition of the epithelial phenotype.      
Docetaxel has many effects on prostate tumor cells, including microtubule 
stabilization but also inhibits AR translocation and increases FOXO1 expression (160).  
Cabazitaxel has the same primary mechanism of action through microtubule stabilization.  
However, cabazitaxel shows efficacy in docetaxel resistant tumors, potentially through 
cabazitaxel’s unique effect on microtubule destabilizing kinesins MCAK and HSET.  The 
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goal is to avoid the seemingly inevitable therapeutic resistance in CRPC patients that is 
one of the biggest challenges in prostate cancer research today.  The scope of these studies 
towards this thesis is to determine new mechanisms driving therapeutic resistance in 
cabazitaxel chemotherapy in advanced prostate cancer. Cabazitaxel’s efficacy in the post-
docetaxel therapeutic landscape stresses the clinical relevance of overcoming cabazitaxel 
resistance to avoid lethal disease.  In the subsequent chapters of this thesis, I describe the 
results from studies investigating the molecular mechanisms of cabazitaxel resistance in in 
vitro and in vivo pre-clinical models of prostate cancer progression. Based on enhanced 
understanding of these novel mechanisms of resistance, I proposed new treatment schemes 
to optimize therapeutic response, and identified molecular targets that will enable new 
treatment therapeutic platforms for combination therapy to increase response and decrease 
resistance in patients with late stage prostate cancer.     
Table 1.  Summary of PCa therapeutics and the cellular 
processes they target. 
 
 
Therapeutics                                       
 
Targeted Process 
Quinazolines Anoikis 
Taxane Chemotherapy Apoptosis, EMT-MET  
ADT/2nd Generation Anti-Androgens  Apoptosis, EMT  
Integrin Targeting Agents Anoikis 
Anti-Angiogenic Agents Anoikis, Autophagy  
PI3K/Akt/mTOR Inhibitors Apoptosis, Anoikis 
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Figure 1.1: Anatomy and histology of a normal prostate 
gland and BPH.  
 
The prostate is located underneath the male bladder, and encloses the urethra.  There are 
three distinct histological zones.  Benign prostatic hyperplasia (BPH) classically originates 
in the transitional zone, and is defined by increased proliferation of both epithelium and 
stroma on histological staining.  Figure from Chughtai et al., 2016. Nature Reviews.  (3).  
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Figure 1.2: AR axis targeting therapeutics   
 
The hypothalamus-pituitary axis controls testicular androgen synthesis by regulating the 
release of luteinizing hormone (LH) from the pituitary. LHRH analogs Leuprolide and 
Goserelin disrupt this through suppression of LH release.  Orchiectomy (surgical 
castration) removes testosterone production from the testes.  Finasteride and dutasteride 
inhibit testosterone conversion to DHT in the prostate. Abiraterone and ketoconazole 
inhibit steroid biosynthesis.  Enzalutamide (MDV3100) works within the cancer cell to 
inhibit AR activity.  AR-variants, through losing the ligand binding domain, are inherently 
resistant to these AR therapies that target ligand production and blocking ligand binding.  
Docetaxel chemotherapy in addition to target microtubule stabilization also prevents AR 
translocation to the nucleus and ultimately transcriptional activity; cabazitaxel 2nd line 
chemotherapy impacts the  microtubule dynamics, and decreased microtubule destabilizing 
kinesin proteins with novel effects on AR binding (See Chapter 2).  
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Figure 1.3: Androgen Receptor and Variants Share the N-
Terminal Domain.   
 
The full length AR protein is translated from exons 1-8, containing the NTD, DNA binding 
domain (DBD), hinge domain, and ligand binding domain (LBD) that binds DHT.  AR 
splice variants have modified or deleted domains.  The most common deletion in AR-
variants is the LBD domain, which renders the AR ligand independent and constitutively 
active due to no longer requiring DHT binding for activation. Modified from Van der Steen 
et al., 2013. International Journal of Molecular Sciences. (210).  
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Figure 1.4: Taxane Mechanism of Antitumor Action.  
 
Docetaxel and cabazitaxel prevent microtubule depolymerizing into tubulin monomers.  
Docetaxel prevents AR translocation to the nucleus, transported by a yet to be identified 
microtubule transport protein.  Cabazitaxel blocks the activity and lowers protein level of 
microtubule-depolymerizing kinesins.   
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Figure 1.5: Effect of EMT to MET interconversion on 
anoikis sensitivity. 
  
Normal epithelial cells are polarized with strong cell-cell and cell-ECM junctions, securing 
homeostatic control. When cells undergo EMT, they lose polarity and gain a mesenchymal 
phenotype via breakdown of E-cadherin mediated cell-cell interactions.  EMT is 
consequential to increased TGF-β signaling, a change of AR expression, and integrin 
detachment. Reversal of EMT to MET calls for a remarkably dynamic and a highly 
transient phenotype; cells undergoing EMT and becoming mesenchymal upon detachment, 
can potentially resist anoikis, evade death and continue surviving and able to seed 
secondary metastasis.  
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Figure 1.6: EMT and anoikis are navigated by AR and TGF-
β cross-talk signaling.  
 
Signaling exchanges by TGF-β (Smad protein effectors) and AR induce EMT through 
activation of transcription factors (Snail and Twist) that transcriptionally repress E-
Cadherin expression. Degradation of cell-cell junctions consequential to the loss of E-
Cadherin, claudin and occludin lead to anoikis and apoptotic execution via FAS signaling 
and caspase-8 activation.  FAK/PI3K signaling confers resistance to anoikis via Akt 
activation, caspase blocking and NFκB activation.  
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Figure 1.7: Chemical Structures of FDA-approved 
Therapeutics for Prostate Cancer Treatment  
 
Chemical structures of select therapeutic agents FDA-approved (antiandrogens and 
taxane chemotherapeutics) used for the treatment of patients with advanced prostate 
cancer. (A) 2nd generation antiandrogens  Enzalutamide, (B) Abiraterone acetate, (C) 1st 
line chemotherapy Docetaxel, (D) 2nd line chemotherapy Cabazitaxel.  Red Circle 
emphasizes the structural difference between docetaxel and cabazitaxel.   
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Chapter Two: Impact of Androgens on Therapeutic 
Response to Chemotherapy in Models of Advanced 
Prostate Cancer  
 
Background and Significance 
 
In early stage, localized disease, patients are treated with radiation therapy and/or 
radical prostatectomy surgery. If disease spreads, patients with metastatic prostate cancer 
are treated with ADT to block the growth stimulating effect that circulating androgens have 
on prostate cancer (15). In some patients, ADT leads to the emergence of castration 
resistant prostate cancer (CRPC) and the cancer no longer responds to ADT. Targeting 
androgen signaling through combination of anti-androgens and microtubule targeted 
chemotherapy has survival benefits for patients with metastatic CRPC (mCRPC), but 
therapeutic resistance ultimately develops in a majority of patients, resulting in lethal 
disease (79-82). Therapy resistance can result from the addiction of CRPC cells to AR 
signaling and constitutive activation of ligand independent AR splice variants (83). Many 
of the AR variants have lost the ligand binding domain, conferring constitutive AR activity 
independent of ligand/androgen binding (100).  The most clinically relevant AR variant, 
AR-v7, has been linked to increased ADT resistance, decreased survival, and poor clinical 
outcomes; however, AR-v7 detection is not associated with primary resistance to taxane 
chemotherapy, indicating that AR-v7 positive patients may respond better to taxanes than 
to AR-targeting therapies (83, 100).   
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  Taxane chemotherapy is the standard of care for patients with metastatic CRPC 
who develop resistance to second generation anti-androgens such as abiraterone or 
enzalutamide.  For over a decade, taxanes were the only class of Food and Drug 
Administration (FDA)-approved chemotherapeutic agents to confer additional survival and 
palliative benefit to CRPC patients (113, 114). Second line taxane, cabazitaxel (Jevtana), 
was optimized from first line taxane chemotherapy (docetaxel, paclitaxel) for increased 
cellular retention due to its lower affinity for the p-glycoprotein efflux pump (114).  
Taxanes exert antitumor action by stabilizing β-tubulin microtubule subunits, preventing 
microtubule depolymerization which induces G2-M arrest and apoptosis (113).  More 
recent evidence has shown that taxane chemotherapy exerts its antitumor effects in prostate 
cancer by impairing AR transport along the microtubules, resulting in AR cytoplasmic 
sequestration and inhibition of AR activity (59, 75).  
 Cabazitaxel has been shown to target and lower cellular level of microtubule-
binding kinesin protein KIFC1 (HSET) (112). Increased HSET expression has been 
associated with docetaxel resistance (149), and recently a HSET inhibitor CW069 has been 
shown to induce apoptosis and re-sensitize resistant cells to docetaxel treatment (168).  
Currently, the full role of HSET in both ADT and cabazitaxel treatment is poorly 
understood.  
The plasticity of fully differentiated prostate tumor glandular epithelium allows 
individual cells to de-differentiate into mesenchymal-like derivatives via the process of 
epithelial-mesenchymal transition (EMT) and re-differentiate via the reverse process, 
mesenchymal-epithelial transition (MET).  While EMT is a normal process in embryonic 
development (105), it can contribute to developing metastasis and advanced disease (106).  
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EMT is characterized by a loss of epithelial cell markers (e.g. E-cadherin) and gain of 
mesenchymal cell markers (e.g. N-cadherin, vimentin) particularly at the invasive edge of 
a tumor (106).  Tumor cell EMT results from a set of transcriptional reprogramming, 
induced by signals from transforming growth factor-β (TGF-β), insulin-like growth factor-
1 receptor (IGF-1R), fibroblast growth factor receptor (FGFR), and platelet derived growth 
factor receptor (PDGFR) (107, 108). The androgen axis and TGF-β signaling intertwine in 
androgen-sensitive prostate cancer cells (109); moreover, prostate tumor cells undergo 
EMT more readily with a low AR content (59), indicating that there is multilayered 
complexity in the interaction between androgens and TGF-β towards EMT.   
ADT induces EMT in a sub-population of prostate cancer cells (110, 111), and 
cabazitaxel chemotherapy reverses EMT to MET in prostate cancer cells in vitro and in 
vivo (112). In the present study we investigated the impact of cabazitaxel and anti-androgen 
treatment in combination and sequential administration, on prostate tumor cell dynamics. 
The efficacy of sequencing therapies in both androgen responsive and CRPC pre-clinical 
models of advanced prostate cancer was geared towards improving and optimizing the 
therapeutic response of patients with lethal disease.   
 
Experimental Approach 
 
Cell Lines: The human prostate cancer cell lines, the castration-resistant cell line 22Rv1 
and androgen-sensitive LNCaP cells were obtained from American Type Culture 
Collection (ATCC, Manassas, VA). Cells were maintained in RPMI 1640 (Invitrogen, 
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Grand Island, NY) and 10% fetal bovine serum (FBS) (Invitrogen, Grand Island, NY), 
100units/ml penicillin and 100µg/ml streptomycin in a 5% CO2 incubator at 37C. For 
experiments examining responses to androgen, cells were seeded in 10% charcoal-stripped 
serum and phenol-red free RPMI 1640 (Invitrogen, Grand Island, NY) and were stimulated 
every 24hrs with dihydrotestosterone (1nM) (DHT) (Sigma-Aldrich, St. Louis, MO). PC3-
CR (cabazitaxel resistant) cell lines were generated through incremental increase of 
cabazitaxel, starting with 0.5nM, over a period of 2 months.   
Cell Viability Assays: The effect of the various treatments on prostate cancer cell 
viability was evaluated using the Thiazolyl Blue Tetrazolium bromide (MTT) assay. Cells 
were seeded into 24-well plates, grown to 50-65% confluence and treated.  Following 
treatment, media was aspirated and cells rinsed with PBS then treated with 250μl/well MTT 
(1mg/ml) for 30mins at 37°C. After incubation, MTT was aspirated and formazan crystal 
was solubilized with DMSO. Absorbance was measured at 570nm using μQuant 
Spectrophotometer (Biotech Instruments Inc., Winooski, VT). 
In vivo xenograft experiments: All animal experiments were performed in accordance 
with the guidelines approved by the Animal Care and Use Committee of the University of 
Kentucky and according to the NIH (Bethesda, MD) recommendations and reporting 
standards. 6-8 week old male Hsd:Athymic nude Foxn1nu mice (Envigo-Harlan) were 
injected with 22g needle into the right flank of the mice with LNCaP (4x106 cells in 100uL 
media) or 22Rv1 (2x106 cells in 100uL media) mixed with 100uL matrigel (Corning 
356230, Corning, NY).  After tumors were palpable, mice were divided into four groups 5 
mice/group: (i) control group receiving sham castration at start, and vehicle (1:1:18 v/v 
ethanol: polysorbate 80: 5% w/v glucose in sterile water) every 3 days via intraperitoneal 
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injection thereafter, (ii) surgical castration and cabazitaxel (3mg/kg every 3 days), (iii) 
sham castration and cabazitaxel (3mg/kg every 3 days), (iv) castration then cabazitaxel 
(3mg/kg every 3 days) three days after castration.  Prostate tumors were measured three 
times a week, and the volume was calculated using the formula length x width x 0.5236. 
Mice were sacrificed with CO2 gas according to institutionally approved protocols and NIH 
guidelines, and tumors were excised. 
Immunohistochemical Analysis: Tissue specimens from mouse xenograft tumors 
were formalin fixed and paraffin-embedded; sections (5µ) were subjected to immuno-
histochemical analysis using rabbit monoclonal antibodies. E-cadherin antibody was 
obtained from Cell Signaling Technology Inc. (Danvers, MA), rabbit polyclonal antibodies 
against nuclear antigen, Ki67 (cell proliferation marker) and N-cadherin were from Abcam 
Inc. (Cambridge, MA); the rabbit polyclonal antibody against AR was obtained from Santa 
Cruz Biotechnology (Santa Cruz, CA). Sections are exposed to specific primary antibody 
and immunostaining was detected by biotinylated goat anti-rabbit IgG and horseradish 
peroxidase–streptavidin conjugate (Millipore, Billerica, MA). Color development was 
performed using a FAST 3,3′-diaminobenzidine-based kit (Sigma–Aldrich) and 
counterstained with hematoxylin. Images are captured with an Olympus BX51 microscope 
(Olympus America, PA).  The number of Ki-67 immunoreactive positive cells was counted 
from three different fields per section and the average value was determined. 
Apoptosis Detection: The incidence of apoptosis was evaluated in situ using the 
terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) 
assay (Millipore, Billerica, MA). Prostate tissue sections were counterstained with methyl 
green and TUNEL-positive cells were counted per high power field (40x10). Quantitative 
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analysis of apoptosis was done by counting the average number of positive cells from three 
different fields of view per section.  
Co-immunoprecipitation: Cells were lysed using Pierce IP Lysis buffer (Thermo 
Scientific, Rockford IL). Co-IP was performed using a Dynabeads Protein G kit, protocol, 
and reagents (Thermo Scientific, Rockford IL).  Anti-KIFC1 (ab172620) (abcam, 
Cambridge, MA) was used (at a concentration of 5µg/sample) for HSET pull downs.   
Western Blotting: Protein samples were prepared using the NE-PER nuclear-
cytoplasmic fraction kit (Thermo Scientific, Rockford, IL). Protein content was quantified 
using the Pierce BCA Protein Assay Kits (Thermo Scientific) and protein samples were 
subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis (4-15% SDS-
polyacrylamide gels; Bio-Rad, Hercules, CA), and transferred to Hybond-C membranes 
(Amersham Pharmacia Biotech, Piscataway, NJ). Following incubation with primary 
antibody (overnight at 4°C), membranes were exposed to species-specific horseradish 
peroxidase-labeled secondary antibody (Jackson ImmunoResearch Laboratories, West 
Grove, PA). Signal detection was achieved with HyGLO Quick Spray Chemiluminescent 
HRP Antibody Detection Reagent (Denville scientific, Metuchen, NJ).  
Immunofluorescent Confocal Microscopy: Cells were plated (1x105) on chamber 
slides coated with fibronectin (Invitrogen). After 24-48hrs, or at about 40% confluence, 
cells were exposed to medium (RPMI 1640 with 10% CSS) in the presence of DHT (1nM, 
ethanol), cabazitaxel (50nM, ethanol) or in combination of the two agents. Following 
treatment, cells were fixed in 4% (v/v) paraformaldehyde and permeabilized with 0.1% 
Triton X-100 in sterile phosphate buffer saline (PBS). Fixed cells were incubated overnight 
at 4°C with primary antibody.  Fluorescent secondary antibody was applied with gentle 
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rocking and the appropriate Alexa-Fluor (Life Technologies, Grand Island, NY) 
fluorescent secondary (1.5 hrs, room temperature). Slides were mounted using Vectashield 
mounting medium with DAPI and were visualized using a FV1000 Confocal Microscope 
(Markey Cancer Center Core, University of Kentucky) or Zeiss LSM780 (Microscopy 
Core, Icahn School of Medicine at Mount Sinai).  
Targeted mass spectrometry quantification of cabazitaxel: Mass spec analysis 
was done at Cedars Sinai Institute, Los Angeles, CA.  Cell pellets were lysed by adding 
100 μL dionized water to each sample, followed by sonication in a water-bath sonicator. 
Two microliters of 50μg/mL cabazitaxel-d9 (Cayman Chemical, #28488) were spiked into 
each sample as an internal standard. After vortexing, 10 μL solution was used for protein 
concentration measurement using the Pierce 660 nm assay kit (Thermo Scientific) 
according to the manufacturer’s manual. To extract cabazitaxel, 1mL tert-butyl methyl 
ether was added to the remaining solution. The sample tubes were vortexed, incubated in 
a ThermoMixer at 1,200 rpm for 10 min at room temperature, and centrifuged at 16,000× 
g for 10 min at 4°C. The upper layer that contains cabazitaxel and cabazitaxel-d9 was dried 
down in a SpeedVac and reconstituted by 75 μL 50% methanol. To quantify cabazitaxel, a 
parallel reaction monitoring (PRM)-based targeted mass spectrometry assay (Dr. Wei 
Yang’s laboratory; Cedars-Sinai Medical Center) was applied. Briefly, 20 μL solution was 
loaded onto a 15-cm Accucore Vanquish C18 column (Thermo Scientific, #27101-152130) 
and separated by ultraperformance liquid chromatography (UHPLC) at a flow rate of 0.3 
mL/min using an Ultimate 3000 XRS (Thermo Scientific). The mobile phase A and B 
consisted of 2 mM ammonium formate and 100% acetonitrile, respectively. A liquid 
chromatography gradient of 50% B in 1 min, 50-85% B in 2 min, 85% B in 2 min, 85-50% 
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B in 0.1 min, and 50%B in 2.9 min. PRM analysis was conducted using an Orbitrap Fusion 
Lumos Tribrid mass spectrometer (Thermo Scientific) operated in the negative ion mode. 
MS1 scans were acquired with an Orbitrap resolution of 120,000 and a scan range of m/z 
870-900. Target masses include m/z 880.36 and 889.414, which respectively correspond 
to cabazitaxel and cabazitaxel-d9 with a formate adduct. Target-triggered MS2 
fragmentation was performed using higher-energy collisional dissociation (HCD) with 
collision energy of 30%. MS2 scans were acquired with an Orbitrap resolution of 60,000. 
The PRM files were analyzed by Skyline (v4.2) to quantify the m/z 880.376/206.042 and 
889.433/206.042 transitions, which are specific signatures for cabazitaxel and cabazitaxel-
d9, respectively. 
Statistical Analysis: The numerical data are analyzed for statistical significance using 
the un-paired student’s t-test by GraphPad Prism 8. Values are expressed as the mean ± 
standard error of the mean (SEM).  Statistical differences were considered significant at p 
value of <0.05.  
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Table 2. List of primary antibodies used, Chapter Two. 
(IF=immunofluorescence, IP=immunoprecipitation, IHC=immunohistochemistry, 
WB=western blot).  
Target Host Uses Source, Catalog # 
KIFC1/HSET Rabbit IF, IP, WB, IHC Abcam, ab172620 
Androgen Receptor Mouse IF Thermo, MA5-13426 
Androgen Receptor Rabbit WB, IHC Santa Cruz, sc-816 
AR-v7 Rabbit IHC  Revmab, 31-1109-00 
Ki-67 Rabbit IHC Cell Signaling, D2H10 
N-Cadherin Rabbit IHC Santa Cruz, sc-59987 
E-Cadherin Rabbit IHC Cell Signaling, 24E10 
E-cadherin Mouse IF Cell Signaling, 4A2 
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Results 
 
Effect of androgens (DHT) on cell viability response to cabazitaxel 
chemotherapy in vitro: 
 
We first investigated the role of androgens on the in vitro response to cabazitaxel, 
by performing time-course studies in three prostate cancer cell lines with different AR 
status (Figure 2.1, panels A, B and C).  The addition of DHT (1nM) every 24 hours had a 
modest protective effect on CRPC 22Rv1 cells, (harboring full length AR but also variants 
2, 3, 4, 5, 5/6, 7, and 120 (100) (Figure 2.1B). In the androgen-sensitive LNCaP cells, 
containing full length AR and AR variant 3, DHT supplementation had a great protective 
value from 48-96 hours of cabazitaxel treatment (100) (Figure 2.1A).  In the AR-negative 
PC3 cells, DHT also had a great protective effect from 24-96 hours (Figure 2.1C).  A dose 
response of PC3 cells to cabazitaxel with and without DHT (1nM) revealed a delay in 
cytotoxicity and a protective effect provided by DHT supplementation. However, in PC3-
CR, a cabazitaxel resistant cell line developed in our lab, there is no protective effect of 
DHT (Figure 2.2A).  Interestingly, DHT does not have the same protective effect on PC3 
cells when treated with 1st generation taxane, docetaxel (Figure 2.2B).  There is no 
statistically significant increase in viability in PC3 or PC3-CR cells between charcoal 
stripped serum (CSS) and 1nM DHT supplementation in neither a dose response (Figure 
2.3A) nor the  time course analysis (Figure 2.3B).  These data indicate that DHT is 
interfering with cabazitaxel efficacy in a mechanism independent of AR binding and 
growth stimulation through downstream transcription products of the androgen response 
element.   
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Treatment sequencing of ADT and cabazitaxel modifies the tumor dynamics 
in LNCaP and 22Rv1 prostate tumor xenografts:  
 
In order to determine pre-clinical efficacy of combining ADT and sequencing 
therapy by giving ADT first to prime the tumor for cabazitaxel induced MET, we 
investigated the effect of androgens on cabazitaxel chemotherapy in in vivo xenograft 
models of prostate cancer.  20 male, 6-8 week old nude mice were randomized into 4 
treatment groups, as indicated in the treatment scheme (Figure 2.4A).  There was no 
significant change in tumor volume (cm3) between treatment groups in either LNCaP 
(Figure 2.4B) or 22Rv1 tumors (Figure 2.4C).    
Treatment with cabazitaxel three days post-ADT led to an increase in apoptosis in 
androgen sensitive LNCaP cells (Figure 2.5A, B left); but not in castration resistant CRPC 
22Rv1 cells (Figure 2.5C, D left).   As shown on Figure 2.5 (panel B), each treatment 
reduced proliferation as measured by Ki67 staining in LNCaP cells, although sequencing 
cabazitaxel after ADT had the biggest effect (Figure 2.5B, right).  In 22Rv1 xenograft 
models, treatment administration led to reduced cell proliferation when compared to 
control, but sequential application of taxanes and ADT had no effect when comparing the 
treatment groups to each other (Figure 2.5D, right).  Representative images of TUNEL 
(apoptosis detection) and Ki67 staining are shown for the LNCaP and 22Rv1 xenograft 
tumor sections  (Figure 2.5, panels A, C respectively).  Previous work from our group 
established that cabazitaxel induces reversal of EMT to MET (112), consistent with our 
current observations in LNCaP tumors treated with cabazitaxel, as detected by increased 
E-cadherin expression (Figure 2.6 A). Moreover there was a parallel decrease in 
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mesenchymal marker N-cadherin expression in cabazitaxel treated tumors when compared 
to control (Figure 2.6A).  In CRPC 22Rv1 tumors, cabazitaxel does not induce E-cadherin 
expression, but instead causes decrease in both E and N cadherins (Figure 2.6B). ADT 
causes an increase in mesenchymal marker N-cadherin in CRPC 22Rv1 tumors (Figure 
2.6B), indicating the differential response of CRPC to treatment compared to androgen-
sensitive LNCaP xenografts.   
 
Novel targetable interaction between HSET and AR by cabazitaxel:  
 
Cabazitaxel treatment given alone or simultaneously with ADT reduced the number 
of cells with nuclear AR positivity (Figure 2.7A, left).   Nuclear intensity was measured 
via H-Score [as previously described, (211)] and treatment did not induce a marked change 
in nuclear AR intensity (Figure 2.7A, right).  In 22Rv1 xenografts, only cabazitaxel and 
ADT given together resulted in a significant decrease in AR immunoreactivity (Figure 
2.7B, left).  Nuclear AR intensity was widely distributed in 22v1 tumors, with nearly 50% 
of positive cells at intensity of 1. Cabazitaxel treatment decreased the proportion of cells 
that had a low intensity score, while increasing the proportion of high intensity scores 
(Figure 2.7B, right).  LNCaP tumors had a heterogeneous response to ADT when imaging 
for AR intensity, with some tumors showing little to no AR expression and others with 
unchanged AR expression (Figure 2.7C).  22Rv1 CRPC xenograft tumors showed 
consistent AR intensity without any effect by ADT  (Figure 2.7D).  There was increased 
detection of AR V7 however in 22Rv1 CRPC in all three treatment groups compared to 
control (Figure 2.7E).    
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HSET expression in in vivo xenograft tumors:  
 
We previously identified HSET kinesin (KIFC1) as a molecular target of 
cabazitaxel (112); in subsequent studies I subsequently examined the effect of cabazitaxel 
treatment on HSET expression in prostate cancer xenografts.  Analysis of the TCGA 
database (Figure 2.8A) revealed a correlation between HSET mutations in prostate cancer 
with poor survival in Kaplan-Meier survival estimates. This implicates a potentially 
important role of HSET in lethal prostate cancer. Cabazitaxel monotherapy increased 
HSET positive cells (Figure 2.8B, D left), in contrast with the cabazitaxel-induced decrease 
in HSET levels observed consistently in vitro (112). Combination of cabazitaxel and ADT 
decreased HSET positive cells in vivo (Figure 2.7D, left). In 22Rv1 xenografts, there is no 
change in HSET positivity in any treatment groups (Figure 2.7D, right).  
Immunohistochemical images of HSET nuclear localization and intensity in LNCaP 
xenografts (Figure 2.7B) and 22Rv1 xenografts (Figure 2.7C) are shown at 20x (top) and 
100x (bottom) magnification.  
 
HSET and HSET/AR interaction are molecular targets of cabazitaxel:  
 
In vitro confocal microscopy of LNCaP cells show a substantial decrease of HSET 
in cabazitaxel treated (under castrate conditions), with a DHT induced protective effect in  
CBZ treated cells in the presence of DHT (Figure 2.9A).  E-cadherin shows a slight 
increase in intensity and a more uniform, epithelial cell shape after cabazitaxel treatment, 
indicating MET has occurred (Figure 2.9A, top row).  The results from confocal 
microscope analysis shown on Figure 2.9 (Panel B), indicate that LNCaP cells in CSS there 
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increased AR expression in response to DHT (as expected), and reduced AR expression 
when cells were treated with cabazitaxel. Cells exhibited high HSET or AR, and in the 
presence of androgens (DHT) there was an increased association of AR-HSET.  
Significantly, cells positive for AR were not affected by cabazitaxel induced multi-
nucleation nor were undergoing apoptosis. Co-localized nuclei with AR/HSET are 
highlighted with a yellow arrow (Figure 2.9B, bottom right).   
Previous work has shown cabazitaxel treatment decreases HSET expression in 
LNCaP cells (112).  In the present studies our findings in the PC3 androgen-independent 
cells resonate with the original evidence (Figure 2.10A). This association was further 
supported by co-immunoprecipitation of LNCaP lysate; As shown on Figure 2.10, panel 
B, the interaction between AR and HSET, is partially blocked partly by cabazitaxel 
treatment, after 24hrs  (50nM) and blocked completely at 48 and 72 hours of treatment in 
FBS cultured cells (Figure 2.10B).  In castrate (CSS) conditions, there is no detectable AR-
HSET binding. After 48hours of exposure to DHT (1nM), the AR-HSET association was 
detected, but it was antagonized by cabazitaxel (50nM) (Figure 2.10C).   
At a lower dose of cabazitaxel, there is still a cytotoxic delay when DHT is present.  
LNCaP cells treated with cabazitaxel (35nM) with and without DHT, exhibit a delayed loss 
of cell viability under androgenic conditions (DHT is present) (Figure 2.11A).  Mass 
spectrometry analysis shows that there is no statistical change in intracellular cabazitaxel 
level when LNCaP cells are treated with cabazitaxel (50nM) with or without (1nM) (Figure 
2.11B). A proposed schema of the results is shown (Figure 2.12A).   
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Conclusions 
 
The emergence of cabazitaxel as a 2nd line taxane chemotherapy effective post-
docetaxel was an important step forward to combatting CRPC and improvement in patient 
survival (114). While cabazitaxel exerts the same “classic” stabilization of microtubules as 
docetaxel, additional mechanisms have been revealed as drivers of therapeutic response 
(114). Recently, growing molecular evidence has revealed targetable mechanisms 
contributing to therapeutic resistance to docetaxel in CRPC including ERG (212), and 
Notch/Hedgehog signaling pathways (213, 214). The pre-clinical efficacy of cabazitaxel 
for prostate cancer was first determined in AR negative cell line DU-145 (114), and has 
later been established in a panel of prostate cancer cell lines with different AR profiles 
(112).  One of the major clinical challenges in the treatment of advanced metastatic prostate 
cancer, is the understanding that despite the monumental involvement of AR and androgen 
signaling as drivers of prostate cancer progression, in the clinical setting the AR status does 
not single handedly determine sensitivity to cabazitaxel (112). Significantly the presence 
of AR-v7, a splice variant commonly associated with advanced disease, is not associated 
with primary resistance to taxane chemotherapy (83, 215).  Our findings are in accord with 
evidence reported by other investigators that the therapeutic response to cabazitaxel is 
significantly modified by the presence of testosterone in AR-containing, hormone 
responsive, pre-clinical models of prostate cancer (216).   
Sequencing cabazitaxel after ADT in androgen responsive LNCaP models had a 
more advantageous effect than in the 22Rv1 CRPC model.  While tumor volume showed 
no significant changes between treatment groups (Figure 2.3B-C), there is a shift in the 
biology within the tumor towards MET in the androgen sensitive LNCaP model.  These 
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findings provide proof of-principle that that sequential treatment with taxane chemotherapy 
is more effective earlier on in prostate cancer progression to optimize therapeutic response. 
The 22Rv1 cell model is more representative of CRPC and our data indicate that ADT and 
cabazitaxel combination fails to provide enhance efficacy. In contrast, in the LNCaP 
(androgen sensitive) model we found a significant increase in apoptosis and decrease in 
proliferation when cabazitaxel is given immediately following ADT.   
We speculate that ADT is “priming” the cell for cabazitaxel to induce apoptosis, 
before resistance to ADT and EMT occurs. In addition, cabazitaxel-induced MET (177) 
can work in tandem with ADT to decrease cancer progression in androgen sensitive 
models.  We thus propose that cabazitaxel and ADT sequencing would be more effective 
if given earlier in the treatment scheme for patients, prior to the emergence of CRPC.  In 
the STAMPEDE trials, patients with metastatic disease (550 men) who started docetaxel 
therapy a median of 9 weeks after beginning ADT, showed a 22% reduction in risk of all-
cause death and a median of 10 months increased survival(126). In patients with non-
metastatic disease (31 men), no benefit was determined by adding docetaxel after ADT 
(126).  These STAMPEDE results indicate that 1st generation taxane docetaxel is effective 
in metastatic disease.  Our data indicates that there is potential therapeutic value in 
attempting a similar trial with ADT and cabazitaxel in patients to test for therapeutic value.  
Our data indicate that DHT is interfering with cabazitaxel efficacy, potentially via 
a mechanism independent of AR, gain support from studies by an independent investigative 
team (216). DHT is interfering with cabazitaxel efficacy in the AR-null PC3 prostate 
cancer cell line, indicating that the mechanism is more complicated.  The lack of response 
in cabazitaxel resistant PC3-CR cells to DHT indicates that developing cabazitaxel 
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resistance includes breaking away from the effect that DHT has on the cell.  Aside from 
AR binding, DHT has been shown to protect against apoptosis induction in glial cells (217), 
and induce Akt phosphorylation (217, 218). Considering the recent evidence (216, 219, 
220), one may argue that DHT is interfering with cabazitaxel entry into the cell.   
My work led to the first evidence on the interaction of AR and the kinesin 
KIFC1/HSET in prostate cancer cells.  AR has been previously shown to be transported by 
KIF5B (221), and that KIFC1/HSET is downregulated by cabazitaxel (177), but 
cabazitaxel has never been shown to influence the  AR-Kinesin interaction. This is of 
translational significance as it provides a new targeting platform in the AR targeting axis, 
and a druggable protein interaction  independent of the action of the current therapeutics 
available.  Patients with mutated HSET have lower progression free survival in the TCGA 
prostate tumor database (Figure 2.7A), indicating that altered HSET contributes to more 
advanced disease progression.  Preventing AR and AR-variant cellular trafficking by 
inhibiting kinesins, or by blocking interaction, could be a way of blocking AR activity in 
an ADT-independent manner.  Ongoing studies are examining whether the AR variants 
interact with kinesins, and the druggable  value of  such an interaction to impact tumors 
harboring AR variants (222). The schematic diagram on Figure 2.12 summarizes the 
consequences of cabazitaxel treatment on protein effectors and the potential targetable 
interactions between protein effectors that beg for therapeutic exploitation to overcome 
resistance in lethal disease. Impairing AR and AR-variant nuclear transport and activity by 
blocking the kinesin interaction, may lead to a new avenue of blocking AR CRPC driver 
action. Ongoing studies are examining whether the AR variants interact with kinesins, and 
the therapeutic value of compromising such an interaction to impact tumors harboring AR 
 
 
 
66 
variants.  My studies provide new insights into the impact of treatment sequencing 
strategies to overcome therapeutic resistance in advanced prostate cancer. Our findings 
identified a) the antagonistic effect of androgens in the antitumor action of cabazitaxel that 
is overcome by ADT; and b) a novel association, between AR and kinesin HSET, which is 
targeted by cabazitaxel. This evidence is of translational significance in targeting AR-
HSET interactions to improve therapeutic response and survival in patients with lethal 
disease.   
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Figure 2.1:  DHT increases prostate cancer cell viability in 
vitro: Dose response studies.   
(A) Time course of LNCaP cell viability in response to cabazitaxel (50nM) in the presence 
or absence of DHT (1nM). (B) Time course of 22Rv1 cell death response after cabazitaxel 
(50nM) treatment in the presence or absence of DHT (1nM).  (C) Time course response of 
PC3 cells to cabazitaxel (50nM), in the presence or absence of DHT (1nM). Values 
represent the average of three independent experiments performed in duplicate.  (*=p<0.05, 
**=p<0.005, ***=p<0.0005). 
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Figure 2.2: DHT affects cabazitaxel efficacy in AR-negative 
cells. 
 (A) Dose response of PC3 and PC3-CR (cabazitaxel resistant) cells to increasing doses of 
cabazitaxel, in the presence or absence of DHT (96 hours). (B) Dose response of PC3 cells 
to docetaxel with and without DHT (1nM) over 96 hours. All experiments done in phenol-
red free media supplemented with charcoal serum stripped FBS. Values represent the 
average of three independent experiments performed in duplicate.  (*=p<0.05, 
**=p<0.005, ***=p<0.0005). 
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Figure 2.3: DHT monotherapy does not affect cell viability 
in PC3 cells.  
(A) PC3 and PC3-CR dose response to increasing doses of DHT over 96 hours. Results 
show 2 trials, experiment was completed in phenol-red free RPMI with charcoal stripped 
FBS. (B) Time course of PC3 cells with no treatment and with DHT (1nM) over 96 hours. 
All experiments done in phenol-red free media supplemented with charcoal serum stripped 
FBS. Values represent the average of three independent experiments performed in 
duplicate.  (*=p<0.05, **=p<0.005, ***=p<0.0005). 
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Figure 2.4: Prostate tumor xenograft response to cabazitaxel 
and ADT in vivo.  
(A) Treatment scheme for mice (n=5/group). Mice were treated with surgical castration 
(ADT) and cabazitaxel (CBZ, 3mg/kg I.P.) for 14 days. (B, C) Tumor volumes (cm3) of 
LNCaP (A) and 22Rv1 (B) xenografts, averaged within treatment groups (n=4).   
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Figure 2.5:  Effect of cabazitaxel and ADT on prostate tumor 
growth.  
 
(A). Representative images (20X magnification) of LNCaP prostate xenograft tumors after 
TUNEL (top) and Ki-67 staining (bottom).  Scale bar indicates 100 µm.  (B) Left – LNCaP 
TUNEL positive cells were quantified. Right – LNCaP Ki67 positive cells were quantified 
(C) Representative images (20X magnification) of 22Rv1 prostate xenograft tumors after 
TUNEL (top) and Ki-67 staining (bottom). Scale bar indicates 100 µm. (D) Left – 22Rv1 
TUNEL positive cells were quantified.  Right – 22Rv1 Ki67 positive cells were quantified. 
(All counting done at 40X, 3 fields/tumor, 2 independent observers.  *=p<0.05, 
**=p<0.005). 
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Figure 2.6: Reversal of EMT to MET in advanced prostate 
tumor xenografts, androgen sensitive LNCaP and CRPC 
22Rv1.   
 
(A) Profiling protein markers of EMT Representative images (20X magnification) of 
LNCaP xenograft tumors after epithelial marker E-cadherin staining (top) and 
mesenchymal marker N-cadherin (bottom). Cabazitaxel treatment increasing E-cadherin 
expression and decreasing N-cadherin expression is indicative of EMT reversal into MET. 
(B) Representative images (20X magnification) of CRPC 22Rv1 xenograft tumors after E-
cadherin staining (top) and N-cadherin (bottom). Representative images from 4-5 tumors 
per treatment group.  Cabazitaxel induced MET is not present in 22Rv1 xenograft tumors 
as it is in LNCaP tumors (A).   Scale bar indicates 100 µm. 
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Figure 2.7: Effect of ADT and cabazitaxel on AR expression 
in prostate tumor xenografts.  
(A) Left – LNCaP AR positive cells were quantified. Right – LNCaP nuclear AR strength 
was quantified by H-Score. (B) Left – 22Rv1 AR positive cells were quantified. Right – 
22Rv1 nuclear AR strength was quantified by H-Score as previously described (211).  (C) 
Characteristic images of AR immunoreactivity in LNCaP tumor xenografts, magnification 
at 20x.  Heterogeneity within CBZ + ADT and CBZ post ADT treatment groups is shown 
with 2 images vertically aligned.  Scale bar indicates 100 µm. (D) AR 
immunohistochemical detection in prostate tumor sections shown at 20x.  Scale bar 
indicates 100 µm. (E) 22Rv1 AR-v7 immunohistochemistry, shown at 20x and 100x 
magnification.  Treatment with cabazitaxel increases AR-v7 expression in monotherapy 
and in combination with ADT, while sequencing cabazitaxel post ADT has a diminished 
increase in AR-v7 expression.  Shown, representative images from 4-5 tumors per 
treatment group.  Scale bar indicates 100 µm (20x images) and 20µm (100x images). 
*=p<0.05, **=p<0.005.  
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Figure 2.8: Significance of HSET Kinesin in Prostate 
Cancer.  
 
(A) HSET mutations in the prostate ate TCGA database decreases progression free Kaplan-
Meier estimate.  Accessed via cBioPortal on November 25, 2019, querying 1329 samples.  
Mutations were found in 4 of the queried samples. (B) HSET immunohistochemistry for 
LNCaP treated xenografts, 20x and 100x magnification. (C) HSET immunohistochemistry 
for 22Rv1 treated xenografts, 20x and 100x magnification. (D) Left – HSET positive cells 
were quantified in LNCaP tumors.  Right – HSET positive cells were quantified in 22Rv1 
tumors.  (*=p<0.05, error bars represent SEM).  Representative images from 4-5 tumors 
per treatment group.  Scale bar indicates 100  µm (20x images) and 20µm (100x images). 
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Figure 2.9: Effect of cabazitaxel treatment on kinesin and 
AR expression and localization.  
 
(A) Confocal microscopy analysis of HSET and E-Cadherin (100x magnification) of 
LNCaP cells treated with cabazitaxel (50nM), DHT (1nM), or combination for 48 hours 
and imaged for E-cadherin as marker of EMT (Alexafluor 594), HSET (Alexafluor 488), 
and DAPI.  Cabazitaxel treatment caused a decrease in HSET expression, which was 
restored with DHT. (B) Confocal microscopy images (100x) of LNCaP cells in charcoal 
stripped FBS, phenol-red free media treated with 50nM cabazitaxel, DHT (1nM), or 
combination for 48hours and imaged for AR  (Alexafluor 594), HSET (Alexafluor 488), 
and DAPI. Arrows highlight cells with AR/HSET co-localization. Nuclei are positive for 
either HSET or AR, but not both, except in DHT monotherapy treated cells.  
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Figure 2.10: HSET and HSET/AR interaction are molecular 
targets of cabazitaxel.  
(A) Cabazitaxel (50nM) decreases HSET expression over 72 hours of treatment in PC3, in 
FBS supplemented media. (B) HSET co-immunoprecipitation of LNCaP cells treated with 
50nM cabazitaxel, in FBS supplemented media. (C) HSET co-immunoprecipitation of 
LNCaP cells in CSS supplemented, phenol-red free media treated with cabazitaxel (50nM) 
and DHT (1nM); the protein profile shows the effect of cabazitaxel on reducing the 
association between the two proteins. 
  
86 
 
 86 
Figure 2.11: DHT challenges cabazitaxel effect in vitro in 
prostate cancer cells. 
(A) 1nM DHT increases cell viability in LNCaP cells treated with cabazitaxel (35nM). (B) 
LNCaP cells treated with cabazitaxel (50nM) with and without DHT (1nM) for 48hours 
were analyzed for intracellular cabazitaxel level.  
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Figure 2.12: Interface of cabazitaxel and ADT on AR and 
HSET cellular distribution  
 
(A) Scheme of combining ADT and cabazitaxel and the effects on select intracellular 
elements. Cytosolic AR binds DHT and translocates to the nucleus, where it aids 
transcription of AR related genes, including downstream effects on growth, proliferation, 
and EMT.  AR-HSET associate upon DHT stimulation, blocked by cabazitaxel, with 
unknown effects on translocation.  Cabazitaxel lowers intracellular level of HSET 
independently of AR-HSET interaction.  ADT blocks both extracellular testosterone (T) 
and intracellular DHT.  Testosterone enters the cell through SLCO1B3 transporter, and 
cabazitaxel is proposed to enter the cell through the same transporter.   
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Chapter Three: Androgen Independent Contributor to 
Prostate Cancer Therapeutic Resistance  
 Significance  
 
Therapy resistant prostate cancer is a complex, multi-faceted disease.  In the 
previous chapter, I discussed the validity of therapeutic sequencing to optimize response 
to cabazitaxel chemotherapy, and uncovered the effect of circulating androgens on 
cabazitaxel efficacy.  In this chapter, I explore a potential mechanism if DHT interferes 
with cabazitaxel chemotherapy, uncovered by the cabazitaxel resistant cell line PC3-CR.  
The membrane transporter protein SLCO1B3, also referred to as OATP1B3, was identified 
to be involved in cabazitaxel resistance through analysis of cabazitaxel resistant cell line 
PC3-CR.  SLCO1B3 has been identified within recent years to be involved in docetaxel as 
well as testosterone cellular uptake (216, 219, 223, 224).   
Bcl-2 (B-cell lymphoma 2) is a pro-survival protein that has been identified in 
prostate cancer therapeutic resistance (36, 225).  Bcl-2 is found in the basal epithelium of 
the prostate, and is closely tied to androgen signaling (226, 227). ADT has been shown to 
increase Bcl-2 expression in the prostate, directly contributing towards therapeutic 
resistance and androgen independent disease (227-229).  Overexpression of bcl-2 as  a 
critical apoptosis suppressor and driver of prostate cancer apoptosis evasion  has also been 
shown to be associated with progression from androgen-dependent disease to the more 
aggressive androgen-independent disease stage (230). Targeting Bcl-2, through both 
pharmacologic inhibition and altering protein levels, is of great interest in prostate cancer.  
Research has shown that decreasing Bcl-2 expression through antisense transcript increases 
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apoptosis and sensitizes in vitro prostate cancer cells to chemotherapy (231).  For radiation 
therapy, the Bcl-2 ratio with its pro-apoptotic family member Bax was predictive of a 
patients’ response to radiation (226) and Bcl-2 overexpression decreases apopotosis when 
prostate cancer cells were exposed to radiation (225).  Pharmacologic inhibition of Bcl-2 
increased efficacy of docetaxel therapy in prostate cancer cells through increasing 
apoptosis induction, indicating the therapeutic value of combination therapy for resistant 
disease (232).   
To interrogate mechanisms of  clinical significance contributing to therapeutic 
resistance of prostate cancer patients with advanced disease we utilized pre-clinical, PDX 
models from patients with metastatic CRPC resistant to cabazitaxel in collaboration with 
by Dr. Nora Navone and Chris Logothetis at MD Anderson Cancer Center, Houston TX 
(233, 234).  These PDX samples are from patients who have metastatic CRPC, and have 
been treated with radiation, ADT, and chemotherapy including 2nd line taxane 
chemotherapy, cabazitaxel.  In the following study the tumors are profiled for EMT 
phenotype, and expression and cellular localization of HSET kinesin, and SLCO1B3 
transporter.      
  Our hypothesis is that the membrane transporter protein SLCO1B3 and kinesin 
HSET expression and cellular distribution are affected by androgens and can impact 
cabazitaxel uptake, ultimately affecting drug resistance and therapeutic response among 
selected prostate tumor cell populations.  In the following chapter I described the results of 
the investigation of alternative mechanisms of resistance in cabazitaxel chemotherapy, 
potential therapeutic value of sequential targeting of AR and microtubules as a mechanisms 
of overcoming treatment resistance in advanced prostate tumors.   
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Approach 
 
Cell Lines: The human prostate cancer cell lines, PC3 (androgen independent, AR-
negative), androgen-sensitive LNCaP cells were obtained from American Type Culture 
Collection (ATCC, Manassas, VA). Cells were maintained in RPMI 1640 (Invitrogen, 
Grand Island, NY) and 10% fetal bovine serum (FBS) (Invitrogen, Grand Island, NY), 
100units/ml penicillin and 100µg/ml streptomycin in a 5% CO2 incubator at 37C. For 
experiments examining responses to androgen, cells were seeded in 10% charcoal-stripped 
serum and phenol-red free RPMI 1640 (Invitrogen, Grand Island, NY) and were stimulated 
every 24hrs with dihydrotestosterone (1nM) (DHT) (Sigma-Aldrich, St. Louis, MO). PC3-
CR (cabazitaxel resistant) cell lines were generated through incremental increase of 
cabazitaxel, starting with 0.5nM, over a period of 2 months.   
Cell Viability Assays: The effect of the various treatments on prostate cancer cell 
viability was evaluated using the Thiazolyl Blue Tetrazolium bromide (MTT) assay. Cells 
were seeded into 24-well plates, grown to 50-65% confluence and treated.  Following 
treatment, media was aspirated and cells rinsed with PBS then treated with 250μl/well MTT 
(1mg/ml) for 30mins at 37°C. After incubation, MTT was aspirated and formazan crystal 
was solubilized with DMSO. Absorbance was measured at 570nm using μQuant 
Spectrophotometer (Biotech Instruments Inc., Winooski, VT). 
In vitro Cell Migration and Invasion: Prostate cancer cells was analyzed via wound 
assay. Cells (104 cells/well) were seeded in 6 well plates, allowed to grow to 60-70% density 
of cell monolayer and a wound was induced using a pipet tip. After wounding, cells were 
exposed to cabazitaxel. The number of migrating cells was counted in three different fields, 
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under microscopic examination. Invasion potential was evaluated using a Biocat Matrigel 
Transwell Chamber (Beckon Dickinson, Franklin Lakes, NJ). Cells were seeded into the 
upper chamber of a transwell insert pre-coated with matrigel in serum-free medium (50,000 
cells/well). After 24hrs non-invading cells were removed from the upper chamber and 
invading cells were stained with Diff-Quick Solution (IMEB Inc., San Marcos, CA). 
 
In vivo Xenograft Models of Advanced Prostate Cancer: All animal experiments 
were performed in accordance with the guidelines approved by the Animal Care and Use 
Committee of the University of Kentucky and according to the NIH (Bethesda, MD) 
recommendations and reporting standards. 6-8 week old male Hsd:Athymic nude Foxn1nu 
mice (Envigo-Harlan) were injected with 22g needle into the right flank of the mice with 
PC3 cells (4x106 cells in 100uL media).  After tumors were palpable, mice were divided 
into two groups 5 mice/group: (i) control group receiving vehicle (1:1:18 v/v ethanol: 
polysorbate 80: 5% w/v glucose in sterile water) every 3 days via intraperitoneal injection 
thereafter, (ii) cabazitaxel (3mg/kg every 3 days).  Prostate tumors were measured three 
times a week, and the volume was calculated using the formula length x width x 0.5236. 
Mice were sacrificed with CO2 gas according to institutionally approved protocols and NIH 
guidelines, and tumors were excised. 
Immunohistochemical Analysis: Tissue specimens from mouse xenograft tumors 
were formalin fixed and paraffin-embedded; sections (5µ) are subjected to immuno-
histochemical analysis using rabbit monoclonal antibodies. E-cadherin antibody was 
obtained from Cell Signaling Technology Inc. (Danvers, MA), rabbit polyclonal antibodies 
against nuclear antigen, Ki67 (cell proliferation marker) and N-cadherin were from Abcam 
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Inc. (Cambridge, MA); the rabbit polyclonal antibody against AR was obtained from Santa 
Cruz Biotechnology (Santa Cruz, CA). Sections are exposed to specific primary antibody 
and immunostaining was detected by biotinylated goat anti-rabbit IgG and horseradish 
peroxidase–streptavidin conjugate (Millipore, Billerica, MA). Color development was 
performed using a FAST 3,3′-diaminobenzidine-based kit (Sigma–Aldrich) and 
counterstained with hematoxylin. Images are captured with an Olympus BX51 microscope 
(Olympus America, PA).  The number of Ki-67 immunoreactive positive cells was counted 
from three different fields per section and the average value was determined. 
Apoptosis Detection: The incidence of apoptosis was evaluated in situ using the 
terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) 
assay (Millipore, Billerica, MA). Prostate tissue sections were counterstained with methyl 
green and TUNEL-positive cells were counted per high power field (40x10). Quantitative 
analysis of apoptosis was done by counting the average number of positive cells from three 
different fields of view per section.  
Western Blotting: Protein samples were prepared using the NE-PER nuclear-
cytoplasmic fraction kit (Thermo Scientific, Rockford, IL). Protein content was quantified 
using the Pierce BCA Protein Assay Kits (Thermo Scientific) and protein samples were 
subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis (4-15% SDS-
polyacrylamide gels; Bio-Rad, Hercules, CA), and transferred to Hybond-C membranes 
(Amersham Pharmacia Biotech, Piscataway, NJ). Following incubation with primary 
antibody (overnight at 4°C), membranes were exposed to species-specific horseradish 
peroxidase-labeled secondary antibody (Jackson ImmunoResearch Laboratories, West 
Grove, PA). Signal detection was achieved with HyGLO Quick Spray Chemiluminescent 
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HRP Antibody Detection Reagent (Denville scientific, Metuchen, NJ).  
Immunofluorescent Confocal Microscopy: Cells were plated (1x105) on chamber 
slides coated with fibronectin (Invitrogen). After 24-48 hrs, or at about 40% confluence, 
cells were exposed to medium (RPMI 1640 with 10% CSS) in the presence of DHT (1nM, 
ethanol), cabazitaxel (50nM, ethanol) or in combination of the two agents. Following 
treatment, cells were fixed in 4% (v/v) paraformaldehyde and permeabilized with 0.1% 
Triton X-100 in sterile phosphate buffer saline (PBS). Fixed cells were incubated overnight 
at 4°C with primary antibody.  Fluorescent secondary antibody was applied with gentle 
rocking and the appropriate Alexa-Fluor (Life Technologies, Grand Island, NY) 
fluorescent secondary (1.5 hrs, room temperature). Slides were mounted using Vectashield 
mounting medium with DAPI and were visualized using a FV1000 Confocal Microscope 
(Markey Cancer Center Core, University of Kentucky) or Zeiss LSM780 (Microscopy 
Core, Icahn School of Medicine at Mount Sinai).  
Quantitative real-time reverse transcription polymerase chain reaction 
analysis: Molecular profiling was conducted using real-time polymerase chain reaction 
(PCR) analysis of prostate cancer cells. Total RNA was extracted from prostate cancer cells 
using TRIzol reagent (Invitrogen/Life Technologies) and was subjected (1 mg) to reverse 
transcription into complementary DNA using a reverse transcription kit from Promega 
(Madison, WI) under the following conditions: 25°C for 10 minutes, 42°C for 60minutes, 
and 95°C for 5minutes. Primer pairs and TaqMan probes (Applied Biosystems, Foster City, 
CA) were used to determine Snail (SNAI1, Hs00195591_m1) Slug (SNAI2, 
Hs00950344_m1), and E-cadherin (CDH1, Mm01247357_m1) gene expression. Primer 
pairs to assess Twist-1 messenger RNA (mRNA) expression were designed using Primer 
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Express software (Applied Biosystems, Branchburg, NJ). The following primers were 
used: Twist-1, forward, 50CCGGAGACCTAGATGTCATTGTT-30, reverse, 50-
AGTTATCCAGCTCCAGAGTCTCTAGAC-30. Real-time PCR was conducted in an 
ABI Prism 7300 system (Applied Biosystems, Branchburg, NJ) in TaqMan Fast universal 
PCR master mix (Life Technologies, Austin, TX) and Power SYBR Green PCR master 
mix (Life Technologies, Woolston Warrington, UK). Numerical data (normalized to 18S 
mRNA and b-actin levels) indicate mean values 6 standard error of the mean (SEM; n = 
4–6). 
RNA-sequencing analysis: RNA-seq analysis was done using the Human Clariom-S 
array analysis with the assistance of the University of Kentucky Microarray Core Facility. 
Total RNA was extracted from prostate cancer cells using TRIzol reagent (Invitrogen/Life 
Technologies) and recommended protocol for RNA-isolation.  Pathway association studies 
were completed using NIH DAVID software KEGG pathway association analysis.  
Targeted Mass spectrometry Quantification of Cabazitaxel: Mass spec analysis 
was done at Cedars Sinai Institute, Los Angeles, CA.  Cell pellets were lysed by adding 
100 μL dionized water to each sample, followed by sonication in a water-bath sonicator. 
Two microliters of 50 μg/mL cabazitaxel-d9 (Cayman Chemical, #28488) were spiked into 
each sample as an internal standard. After vortexing, 10 μL solution was used for protein 
concentration measurement using the Pierce 660 nm assay kit (Thermo Scientific) 
according to the manufacturer’s manual. To extract cabazitaxel, 1 mL tert-butyl methyl 
ether was added to the remaining solution. The sample tubes were vortexed, incubated in 
a ThermoMixer at 1,200 rpm for 10 min at room temperature, and centrifuged at 16,000× 
g for 10 min at 4°C. The upper layer that contains cabazitaxel and cabazitaxel-d9 was dried 
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down in a SpeedVac and reconstituted by 75 μL 50% methanol. To quantify cabazitaxel, a 
parallel reaction monitoring (PRM)-based targeted mass spectrometry assay established by 
Dr. Wei Yang’s laboratory at Cedars-Sinai Medical Center was applied. Briefly, 20 μL 
solution was loaded onto a 15-cm Accucore Vanquish C18 column (Thermo Scientific, 
#27101-152130) and separated by ultraperformance liquid chromatography (UHPLC) at a 
flow rate of 0.3 mL/min using an Ultimate 3000 XRS (Thermo Scientific). The mobile 
phase A and B consisted of 2 mM ammonium formate and 100% acetonitrile, respectively. 
A liquid chromatography gradient of 50% B in 1 min, 50-85% B in 2 min, 85% B in 2 min, 
85-50% B in 0.1 min, and 50%B in 2.9 min. PRM analysis was conducted using an Orbitrap 
Fusion Lumos Tribrid mass spectrometer (Thermo Scientific) operated in the negative ion 
mode. MS1 scans were acquired with an Orbitrap resolution of 120,000 and a scan range 
of m/z 870-900. Target masses include m/z 880.36 and 889.414, which respectively 
correspond to cabazitaxel and cabazitaxel-d9 with a formate adduct. Target-triggered MS2 
fragmentation was performed using higher-energy collisional dissociation (HCD) with 
collision energy of 30%. MS2 scans were acquired with an Orbitrap resolution of 60,000. 
The PRM files were analyzed by Skyline (v4.2) to quantify the m/z 880.376/206.042 and 
889.433/206.042 transitions, which are specific signatures for cabazitaxel and cabazitaxel-
d9, respectively. 
Statistical Analysis: The numerical data are analyzed for statistical significance using 
the un-paired student’s t-test by GraphPad Prism 8. Values are expressed as the mean ± 
standard error of the mean (SEM).  Statistical differences were considered significant at p 
value of <0.05. 
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Table 3. List of primary antibodies used, Chapter Three. 
(IF=immunofluorescence, IP= immunoprecipitation, IHC=immunohistochemistry, 
WB=western blot).  
Target Host Uses Source, Catalog # 
KIFC1/HSET Rabbit IF, IP, WB, IHC Abcam, ab172620 
E-Cadherin Rabbit IHC Cell Signaling, 24E10 
E-cadherin Mouse IF Cell Signaling, 4A2 
SLCO1B3 Rabbit IHC, WB Abcam, ab224064 
Vimentin Rabbit IHC Cell Signaling, D21H3 
Cytokeratin-18 Rabbit IHC Abcam, ab189444 
Β-Tubulin Mouse IF Santa Cruz, sc-5274 
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Results  
 
 PC3 prostate cancer xenografts (androgen-independent), treated with either vehicle 
or cabazitaxel for 14 days showed a statistically significant decrease in tumor growth in 
cabazitaxel treated mice (Figure 3.1A).  Cabazitaxel treated tumors had significantly less 
vimentin expression, indicating that treatment induced MET and decreased mesenchymal 
characteristics (Figure 3.1B).  In addition to decreasing mesenchymal markers, cabazitaxel 
treatment induced apoptosis induction in PC3 xenograft tumors significantly (Figure 3.1C).  
HSET kinesin protein, in the control tumors, was located primarily in the nucleus, with 
occasional cells having positive staining in the cytosol; however, in cabazitaxel treated 
tumors, HSET became localized primarily in the cytosol (Figure 3.2A). This is in contrast 
to in vitro data in LNCaP and 22Rv1 cells previously discussed in Chapter 2.  However, in 
PC3 and PC3-CR cells, cabazitaxel treatment for 48 hours (50nM) causes HSET to become 
localized to the cytosol in PC3 cells.  In cabazitaxel resistant PC3-CR cells, HSET retains 
a cytosolic localization in both untreated and treated cells (Figure 3.2B).    
Cabazitaxel resistant cells, PC3-CR, were developed from parental PC3 cells 
through continual exposure to increasing doses of cabazitaxel.  PC3-CR cells have 
increased cell viability when treated with cabazitaxel for 96 hours when compared to PC3 
cells (Figure 3.3A).  In addition, PC3-CR cells have an inherent cross resistance to 
docetaxel treatment as shown in Figure 3 (Panel B).  Interestingly, PC3-CR cells have a 
more mesenchymal phenotype when compared to the epithelial PC3 parental cells, 
indicating that the cells have undergone EMT as part of the emerging cabazitaxel resistance 
(Figure 3.3C).  Upon undergoing EMT, PC3-CR cells exhibit acquisition of migratory 
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characteristics.  PC3-CR cells have increased migration at 24 and 48 hours when compared 
to parental PC3 cells, and maintain migratory qualities when treated with cabazitaxel 
(50nM and 100nM) (Figure 3.4A).  While PC3 cells are not invasive, PC3-CR cells have 
an average of over 250 invasive cells per matrigel membrane after 48 hours (Figure 3.4B).   
RNA-seq analysis (Human Clariom S) comparing PC3-CR to PC3 gene 
expressions show changes in untreated gene expression between the two cell lines (Figure 
3.5A).  Transcriptional repressors of E-Cadherin (emphasized with blue boxes) had 
variable responses; ZEB1, Slug (SNAI2), and Snail (SNAI1) decreased in expression, 
while Twist (TWIST1) and ZEB2 increased in expression.  E-cadherin (CDH1) expression 
was unchanged in 2 replicates and decreased in one replicate, and N-Cadherin (CDH2) 
expression decreased, contradicting the phenotypic EMT that the cell shape indicated.  
Pathway analysis, completed using NIH DAVID KEGG pathway association showed PC3-
CR cells had increased DNA repair pathways (mismatch repair, homologous 
recombination), cell cycle, oxidative phosphorylation, and pathways in cancer when 
compared to PC3 cells (Figure 3.5B).   
The RNA seq analysis revealed downregulation of the membrane transporter 
SLCO1B3 in the cabazitaxel-resistant prostate cancer cells compared to the PC3 parental 
control cells (Figure 3.5A).  Previous evidence has demonstrated that SLCO1B3 is 
responsible for the transport of docetaxel and testosterone into cells (120, 216, 235).  
SLCO1B3 RNA was confirmed to be decreased in PC3-CR cells via qRT-PCR (Figure 
3.6A), and protein level is non-detectable via western blot (Figure 3.6B).  I hypothesize 
that the effect that DHT has on PC3 cells in vitro, through increasing cell viability despite 
PC3 being an AR-negative cell line, is due to PC3 cells possessing the SLCO1B3 
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transporter while PC3-CR cells do not (Figure 2.2A).  Clinically, SLCO1B3 alterations 
lead to decreased progression free Kaplan-Meier estimate, and decreased overall survival 
(Figure 3.7A) in the TCGA prostate cancer tumor database.  Alterations in SLCO1B3 are 
most commonly a shallow deletion (light blue), and a deep deletion (dark blue), with rare 
amplification (red) within the TCGA database (Figure 3.7B) contributing to the decreased 
months progression free and decreased survival.  
For functional analysis, I performed a knockdown of SLCO1B3 in PC3 cells in 
order to determine the functional consequences of the transporter loss on cabazitaxel 
resistance. Stable shRNA knockdowns were generated, with a shCONTROL vector and 3 
shSLCO1B3 constructs selected.  All three shSLCO1B3 cell lines generated had decreased 
SLCO1B3 protein level when analyzed via western blot (Figure 3.8A).  Dose response 
treatment for a period of 96 hours, demonstrated that shSLCO1B3-C statistically 
significant increase in cell viability to increasing doses of cabazitaxel (Figure 3.8B), 
compared to vector control and shSLCO1B3-A cells.   Unexpectedly, DHT presence in 
PC3 cells significantly increased cabazitaxel uptake into the cell, and knockdown of 
SLCO1B3 (shSLCO1B3-C) also significantly increased cabazitaxel uptake (Figure 3.8C).    
In the untreated controls LNCaP xenograft tumors (Figure 2.3), there was a defined 
membrane localization of SLCO1B3 in vivo.  In response to treatment (either with 
cabazitaxel as a monotherapy or and cabazitaxel and ADT  expression of SLCO1B3 was 
detected as  diffused distribution, with modest changes in the cellular localization of the 
protein with a faint cytosolic localization and no clear membrane boundary  (Figure 3.9A).  
In vitro confocal microscopy of LNCaP cells shows a similar effect.  Untreated (in castrate 
conditions) LNCaP cells have a membrane and cytosolic localization of SLCO1B3, with 
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cabazitaxel treatment slightly lessening signal intensity but not entirely abrogating the 
signal (Figure 3.9B).  Cabazitaxel treatment (50 nM) in the presence of DHT resulted in  
SLCO1B3 protein cytosolic localization without traces of  membrane distribution.  E-
Cadherin, shown in green, is increased in cabazitaxel treated cells and shows that LNCaP 
cells have undergone MET in response to cabazitaxel treatment (Figure 3.9B).   
  B-cell lymphoma 2 (Bcl-2) overexpression in PC3 cells changes response to 
taxane chemotherapy in vitro.  First, a panel of prostate cancer cell lines was profiled for 
Bcl-2 expression (Figure 3.10A), and only PC3-bcl2 cells had detectable Bcl2 expression.  
Bcl-2 overexpression in PC3 cells conferred statistically significant increase in 
viability/decrease in cell death when treated with  docetaxel or paclitaxel chemotherapy 
dose response studies (as expected) (Figure 3.10B).  In contrast, Bcl-2 overexpression 
sensitized prostate cancer cells PC3 cells to cabazitaxel in a dose response study on cell 
viability (Figure 3.10C).  Interestingly enough, Bcl-2 expression increased E-cadherin 
expression in these cells as detected by western blot (Figure 3.10D), suggesting a 
phenotypic reversal of EMT to MET conferred by Bcl-2; moreover there was increased 
expression of pro-mitotic kinesin proteins HSET and MCAK in prostate cancer cells 
overexpressing bcl-2.   
To interrogate mechanisms of clinical significance contributing to therapeutic 
resistance of prostate cancer patients with advanced disease we obtained PDX samples 
established by Drs. Nora Navone and Christopher Logothetis at MD Anderson Cancer 
Center, Houston TX (233, 234). The clinical origin and the pathological characteristics of 
prostate cancer specimens from which the PDX models were established and used in our 
analysis, are summarized on Figure 3.11.  Eight samples were studied, from five, n=5) 
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patients, four of which received cabazitaxel chemotherapy.  Patient 5 has four samples 
obtained longitudinally over time (Patient 5a, 5b, 5c, and 5d), before and after cabazitaxel 
treatment.  The clinicopathological features including tumor site, diagnosis, treatment 
status, and therapies received are summarized on Figure 3.10.   
Two patients, patient 1 and 2, had adenocarcinoma of the prostate.  Patient 1, with 
PDX established from a bone metastasis, was treatment naïve, and is being used as a control 
for this sample set. Patient 2, with PDX established from peritoneal fluid, in contrast, 
received multiple therapies including prostatectomy surgery, radiation, continuous use of 
antiandrogen, and docetaxel with carboplatin followed by cabazitaxel.  The tumor from 
Patient 3, classified as small cell carcinoma, was isolated from a lymph node, and was 
heavily treated with radical prostatectomy, radiation, and antiandrogens.  Patient 4’s PDX 
was isolated from circulating tumor cells (CTC), and is pathologically adenocarcinoma.  
Patient 4 was treated with antiandrogens, radical prostatectomy surgery, then cabazitaxel 
with carboplatin.  Patient 5 had four PDX tumors established from his disease, the first one 
(5a) isolated from pelvic soft tissue and was classified as malignant epitheliod and spindle 
cell neoplasm with osteoid differentiation.  At this point in time, patient 5 had received 
antiandrogens and a VEGF inhibitor.  After sample 5a was isolated, sample 5b was isolated 
from the same patient.  Patient sample 5b was isolated from the prostate, after the patient 
was treated with second generation antiandrogen abiraterone and cabazitaxel with 
carboplatin, and then with DNA targeting agents, and microtubule targeting agent 
vincristine.  Samples 5c and 5d were isolated in the same surgery, 5c was extracted from 
the bladder and 5d was removed from a lymph node.  Both tumors are classified as 
adenocarcinoma with sarcomatoid and small cell carcinoma.  A summary table of all 
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known information about patient samples from PDX tumors can be found in Figure 3.11.  
First, a profile for EMT markers was completed on the PDX tumors.  Patients 1 and 4 had 
substantial E-cadherin staining (Figure 3.12A), with patient 2 having consistent but weaker 
positivity.  Patients 3 and 5 (5a-d) had detectable but extremely weak and diffuse E-
cadherin staining, suggesting these patients had more mesenchymal tumors.  
Complementary staining for mesenchymal marker vimentin showed a similar effect 
(Figure 3.12B).  Patients 1 and 4, with strong E-cadherin, had very weak vimentin staining.  
Patients 2 and 5 (5a-d) had strong positive staining for vimentin, further indicating 
mesenchymal tumors.  Interestingly, patient 5 had increasing vimentin intensity in later 
samples (5c and 5d) indicating that this patient’s tumor became more mesenchymal in 
phenotype as the patient underwent further therapies.  Patient 3, with small cell carcinoma, 
was positive in neither epithelial marker E-Cadherin nor mesenchymal marker vimentin. 
Patients 1 and 4 had the most epithelial character, perhaps due to patient 1 being treatment 
naïve. Patient 4 could possess strong epithelial markers due to MET from extensive 
cabazitaxel with carboplatin chemotherapy (4 cycles) before sample collection or because 
the PDX was generated from circulating tumor cells and not a solid tumor site.  
Cytokeratin-18, a marker of cellular differentiation, was strongly present in the epithelial 
tumors from patients 1 and 4, and weakly in patient 2 (Figure 3.13).  The co-positivity of 
cytokeratin 18 and E-cadherin indicates that EMT reduces cellular differentiation as cells 
become more mesenchymal and mobile in nature.  
We found that the prostate tumor specimens from all the PDX models exhibited 
strong immunoreactivity for nuclear HSET kinesin (Figure 3.14).  Patient 3 had the weakest 
staining, but it was widespread, and there is no visible change in the prevalence of HSET 
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positive cells between the different tumors. HSET is not altered appreciably between 
epithelial and mesenchymal tumors, and that different disease stages does not alter HSET 
expression visibly.  Strong staining for the novel transporter protein, SLCO1B3, was 
detected (in two) of the cabazitaxel resistant tumors  with extremely weak, diffuse staining 
in the other tumors (Figure 3.15).  The strongest SLCO1B3 expression was found in patient 
4, an epithelial phenotype tumor isolated from circulating tumor cells.   
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Conclusions 
 
 Cabazitaxel treatment significantly decreased growth in PC3 xenograft tumors.  
Tumors, along with a statistically significant decrease in growth, showed EMT reversal 
into MET indicated by decreased levels of the mesenchymal marker vimentin.  The EMT 
reversal is indicative of changes in tumor biology independent of tumor volume, but related 
to restoration of an epithelial phenotype that could increase sensitivity to treatment. 
Corresponding with the decreased tumor size, cabazitaxel-treated tumors showed an 
increase in apoptosis, fitting with cabazitaxel primary mechanism of action, apoptosis 
induction through microtubule stabilization.   
Cabazitaxel treatment of PC3 xenografts resulted in nearly complete cytosolic 
localization of HSET.  Since HSET is the only known kinesin in human cells that moves 
cargo towards the (-) end of microtubules, that is, towards the microtubule organizing 
center near the nucleus, locking HSET in the cytosol instead of its normal nuclear location 
would have dramatic effects on HSET functionality (141, 142).  It is possible that the 
reason HSET is responding to cabazitaxel differently in PC3 xenografts than in the LNCaP 
and 22Rv1 xenografts (where HSET was exclusively nuclear in localization) is because 
PC3 cells do not express any androgen receptor.  The AR-HSET interaction discovered in 
Chapter 2 could have more mechanistic consequences in the cell, with AR transport 
providing a critical role for HSET in the nucleus – without AR, HSET could lose a nuclear 
role.  Further research into this hypothesis is necessary.    
The cabazitaxel resistant PC3-CR cell line provided a valuable model for 
investigating cellular differences acquired with cabazitaxel resistance.  Importantly, PC3-
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CR cells were found to be locked in a mesenchymal phenotype, with different cell shape, 
increased migration, and dramatically increased invasion. The observation that PC3-CR 
cells exhibit cross-resistance to docetaxel (1st line taxane chemotherapy) treatment (Figure 
3.3B) supports the functional overlap in terms of taxane mechanism of action with 
cabazitaxel, the 2nd line taxane chemotherapy.  PC3-CR cells also exhibited a cytosolic 
HSET localization, rather than nuclear, as in the cabazitaxel sensitive PC3 cells.   RNA 
sequencing comparing the sensitive and resistant PC3 cells identified membrane 
transporter SLCO1B3, a protein implicated in androgen and docetaxel uptake, as heavily 
downregulated in PC3-CR cells (216, 224). SLCO1B3 has not been investigated in the 
context of cabazitaxel resistance, until our novel findings on SLCO1B3 knockdown 
conferred statistically significant increases in viability when treated with cabazitaxel in 
vitro (Figure 3.8B).  Alterations in SLCO1B3 decrease progression free survival and 
overall survival in the TCGA database, a relevant clinical trial despite the limited sample 
size on the database (Figure 3.7A).  In the future, with larger database availability and 
accessibility increasing, a more extensive analysis of SLCO1B3 protein expression in 
prostate cancer is necessary.  
Finding that SLCO1B3 knockdown increased cabazitaxel cellular uptake in LNCaP 
cells was a paradox.  It is possible that SLCO1B3 knockdown caused the cells to upregulate 
other membrane transporter proteins that therefore caused an increase in cabazitaxel 
uptake, and further research is needed to determine the role of SLCO1B3 in cabazitaxel 
uptake.  Additionally, DHT presence triggered a paradoxical increase in cabazitaxel 
uptake, in contrast to predictions based on previous research.  Once again, determining the 
complicated relationship between DHT, cabazitaxel, and cellular uptake is needed.  LC-
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MS/MS was an incredibly invaluable tool to collect these data, and the data was normalized 
to microgram of lysed intracellular protein.  It would be interesting in the future to 
normalize the amount of cabazitaxel to the number of cells present in the sample to 
determine if there is discrepancies in the data due to cell lysis.   
Despite the information gained from PC3-CR cells, it is not a model without 
weakness.  Cell authentication revealed that while PC3-CR cells are identical in cell 
markers to the parental PC3 line, the cell line became contaminated with mouse origin 
materials, indicative of contamination with a mouse origin cell line.  The data collected 
from the PC3-CR cell line will need to be validated in the future with different cell lines.  
An interesting and paradoxical result was found with Bcl-2 overexpression in 
prostate cancer cell lines.  PC3-bcl2, a cell line overexpressing Bcl-2, was found to be 
resistant to first line taxane chemotherapies docetaxel and paclitaxel.  Being a pro-survival, 
anti-apoptotic protein (36, 225, 230), it was surprising to find that PC3-bcl2 cells were 
more sensitive to second line taxane cabazitaxel (Figure 3.10C).  This effect contradicts 
the main body of literature, and needs to be investigated further in more diverse models.  It 
is possible that, because Bcl-2 inhibitors sensitize human prostate cancer cells to docetaxel 
(124, 125), that Bcl-2 inhibition would be even more effective for cabazitaxel 
chemotherapy and is an attractive target for combination therapy to overcome cabazitaxel 
resistance.  
The patient-derived xenograft tumors allowed a momentary snapshot into the 
biology of advanced prostate cancer that has progressed through cabazitaxel chemotherapy 
in clinical settings.  One of the most interesting conclusions from the PDX results is how 
the tumors, based on staining, fit into either an epithelial or a mesenchymal phenotype.  
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Patient 1, who was treatment naïve, had an epithelial marker positive tumor, with well-
defined E-cadherin expression and no detectable vimentin.  Similarly, patient 4 had an 
epithelial phenotype tumor.  The other tumors had weak or no E-cadherin expression, and 
a corresponding positivity in mesenchymal marker vimentin.  Cytokeratin-18, a marker for 
cellular differentiation, corresponded with E-cadherin expression, further supporting that 
the prostate tumors from patients 1 and 4 are of glandular epithelial phenotype.  
Furthermore the SLCO1B3 membrane localization correlated with epithelial character as 
well.  Patients 1 and 4 had membrane localization, with patient 4 having a cytosolic 
presence as well.  Patient 5 had a transient (5b only) cytosolic presence, but as with the 
other mesenchymal tumors, did not have membrane localization of SLCO1B3.  These data 
support the hypothesis that SLCO1B3 functionally contributes to maintaining an epithelial 
phenotype, perhaps through inducing MET, or if an epithelial cell has more SLCO1B3 
expression (and membrane localization) as a consequence of changes in cell polarity.  This 
work also supports a new avenue for investigation of a potential therapeutic value of 
SLCO1B3, towards overcoming therapeutic resistance and a druggable protein to target in 
order to improve clinical outcome in prostate cancer patients with lethal disease.  Ongoing 
studies focus on establishing a functional link between SLCO1B3 transporter and the 
phenotypic configuration of prostate cancer cells. This will validate my findings in 
profiling the distribution of the transporter in PDX prostate tumor specimens from 
treatment-resistant human tumors as a novel mechanism to induce MET in mesenchymal, 
invasive prostate tumors towards acquisition of re-differentiation properties.   
  
109 
 
 109 
Figure 3.1: Cabazitaxel inhibits androgen independent 
prostate tumor xenograft growth and increases tumor 
apoptosis. 
(A) Male, nude, SCID mice were injected with PC3 human prostate cancer cells and treated 
with either cabazitaxel (3mg/kg) or vehicle (n=5) for 14 days.  A statistically significant 
decrease was found in tumor growth in cabazitaxel treated mice.  (B) 
Immunohistochemical staining of mesenchymal marker vimentin in control/vehicle and 
cabazitaxel treated xenograft tumors. Scale bar indicates 100 µm (20X images) and 20 µm 
(100X images). (C) Cabazitaxel treatment induced statistically significant increase in 
apoptosis in PC3 xenograft tumors.  Each point is representative of one tumor, with an 
average of 6 fields of view quantified at 20X magnification.  *=p<0.05, **=p<0.005 
students t-test.  
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Figure 3.2: Cabazitaxel treatment alters HSET localization 
in androgen-independent prostate cancer cells.   
(A) Immunohistochemical staining of kinesin protein HSET in control/vehicle and 
cabazitaxel treated xenograft tumors.  Scale bar indicates 100 µm (20X images) and 20 µm 
(100X images). (B) Immunofluorescence imaged with confocal microscopy (100X) of β-
tubulin, HSET, and DAPI on PC3 and cabazitaxel resistant PC3-CR cells treated with 
control or cabazitaxel (50nM) for 48 hours, FBS.  HSET is nuclear in untreated PC3 cells, 
and cytosolic in untreated PC3-CR cells. Cabazitaxel treatment alters HSET localization 
in PC3 cells, but not in PC3-CR cells. Scale bars indicates 10 µm. 
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Figure 3.3: EMT phenotype in cabazitaxel resistant cells 
(PC3-CR)   
 
(A) Dose response of parental PC3 and cabazitaxel resistant PC3-CR cells to cabazitaxel, 
96 hours.  (B) Dose response of PC3 and PC3-CR cells to docetaxel, 72 hours.  (C) 
Brightfield images of live, cultured PC3 and PC3-CR cells (10X magnification).  
***=p<0.005, students t-test.  
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Figure 3.4: Cabazitaxel resistance is associated with 
migratory and invasive properties in prostate cancer cells.  
 
(A) The migratory potential of PC3 and PC3-CR cells was assessed via wound healing 
assay after exposure to cabazitaxel treatment for 24 and 48 hours, 0nM, 50nM, and 100nM.  
Cells migrating into the wound were counted on three different fields of view.  (B) Invasive 
potential of untreated PC3 and PC3-CR cells were assessed via matrigel invasion assay for 
24 hours.  Membranes were counted on three different fields of view.   
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Figure 3.5: RNA profile of cabazitaxel resistance. 
(A) Human Clariom S RNA sequencing analysis of PC3 and PC3-CR cells.  Cadherin 
proteins (Red box) E-cadherin (CDH1) and N-cadherin (CDH2).  Transcriptional 
repressors of E-cadherin are shown with blue boxes. (B) NIH DAVID KEGG pathway 
association analysis, fold enrichment compares PC3-CR expression to parental PC3. 
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Figure 3.6: Loss of SLCO1B3 expression in cabazitaxel 
resistant cells.   
(A) mRNA expression of SLCO1B3 was evaluated by RT-PCR analysis. qRT-PCR results 
revealed that untreated  PC3-CR cells exhibited total loss of mRNA expression for the 
transporter compared to PC untreated parental cells (normalized to 18s).  (B) Western blot 
analysis of SLCO1B3 protein expression in untreated PC3 and PC3-CR cells.  
***=p<0.0005, student’s t-test.   
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Figure 3.7: SLCO1B3 alterations correlate with survival: 
TCGA analysis. 
 
(A) Progression free Kaplan-Meier estimate (left) and overall survival Kaplan-Meier 
estimate (right) of patients with alterations in the SLCO1B3 gene (red) compared to no 
alterations (blue).  (B) SLCO1B3 expression, done by RNA Seq, in 2015 TCGA prostate 
database (left), TCGA PanCan prostate database (middle) and TCGA prostate database 
(right).  Gray circles indicate no SLCO1B3 mutation, light blue indicates a shallow copy 
deletion, royal blue indicates a deep copy deletion, red indicates copy number 
amplification.   
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Figure 3.8: SLCO1B3 loss increases both cabazitaxel uptake 
and resistance to cabazitaxel. 
 (A) Stable knockdown of SLCO1B3 using shRNA in PC3 cells decreases SLCO1B3 
protein expression, (compared to shCONTROL).  (B) Cell viability dose response analysis 
of stable knockdown PC3-shSLCO1B3 when treated with increasing doses of cabazitaxel 
for 96 hours.  (C) Intracellular concentration of cabazitaxel measured via mass spec 
analysis and normalized to protein content in three cell lines, PC3 (black), PC3-
shCONTROL (blue), and PC3-shSLCO1B3-C (green) treated with cabazitaxel (50nM) and 
DHT (1nM).  *=p<0.05, **=p<0.005, student’s t-test.    
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Figure 3.9: Treatment with cabazitaxel and ADT decreases 
membrane localization of SLCO1B3.   
 
(A) Immunohistochemistry of SLCO1B3 in LNCaP xenograft tumors.  Representative 
images shown at 20X and 100X magnification.  Scale bar indicates 100 µm (20X images) 
and 20 µm (100X images).  (B)  Immunofluorescence of E-cadherin (green) and SLCO1B3 
(red) in LNCaP cells treated with cabazitaxel (50nM), DHT (1nM) or combination for 48 
hours shows SLCO1B3 cytosolic localization after treatment.  Scale bar indicates 20 µm. 
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Figure 3.10: Bcl-2 overexpression sensitizes PC3 prostate 
cancer cells to cabazitaxel.  
(A) Western blot analysis shows Bcl-2 protein expression in a panel of human prostate 
cancer cell lines.  (B) Cell viability dose response assay of PC3 and PC3-bcl2 cells to 
docetaxel and paclitaxel for 72 hours, demonstrates resistance to treatment, and (C) 
cabazitaxel for 96 hours, showing increased sensitivity to cabazitaxel.  (D)  Western blot 
analysis of PC3 and PC3-bcl2 cells, bcl2 overexpression shows increased bcl2, E-cadherin, 
and kinesins HSET and MCAK.  **=p<0.005, ***=p<0.0005, student’s t-test.  
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Figure 3.11: Patient derived xenografts (PDX) models from 
cabazitaxel treated, metastatic CRPC. 
 
(A) Table of de-identified information of prostate cancer tumors from patients treated 
with cabazitaxel.  Sample date indicates the date at which the tumors were frozen, not 
collected.  Tumor site indicates the location from which the sample was collected.  
Patient 5 has four samples collected from three different surgeries.    
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Figure 3.12: Epithelial and mesenchymal phenotype in PDX 
tumors.   
 
(A) Immunohistochemical staining of PDX tumors for E-cadherin, shown at 20X and 
inserts at 100X magnification.  (B) Corresponding immunohistochemical staining of PDX 
tumors for mesenchymal cytoskeletal element vimentin, shown at 20X and inserts at 100X 
magnification. 
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Figure 3.13: Cellular differentiation corresponds with 
epithelial character in PDX tumors.  
 
(A) Immunohistochemical staining of PDX tumors for marker of cellular differentiation, 
cytokeratin-18, shown at 20X and 100X magnification.  
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Figure 3.14: HSET Kinesin expression is consistent across 
PDX tumors.  
 
(A) Immunohistochemical staining of PDX tumors for HSET kinesin, shown at 20X and 
100X magnification.  HSET is localized in cell nuclei, with rare diffuse cytosolic staining.  
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Figure 3.15: SLCO1B3 expression correlates with epithelial 
phenotype in cabazitaxel resistant prostate tumors. 
(A) Expression and cellular localization of the transporter protein SLCO1B3 was examined 
by immunohistochemistry of paraffin embedded sections of PDX prostate tumors for 
membrane localization.  The images reveal the immunoreactivity for the transporter at 20X 
and 100X magnification.  Protein expression is weak and diffuse, with the strongest stain 
in patient 4, an epithelial phenotype tumor isolated from circulating tumor cells.   
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Chapter Four: Discussion 
 
 The current therapeutic landscape for treatment of prostate cancer is lacking 
options, for CRPC in particular, and in resistant disease.  Understanding the biology that 
underlies therapeutically resistant disease is the primary way to improve treatment options 
and thus improve patient outcome.    
Our findings identified a novel interaction, AR-HSET, which could provide a new 
targetable mechanism to impair AR signaling.  Moreover we show that cabazitaxel and 
ADT in combination and in optimized sequencing is therapeutically effective in androgen-
sensitive prostate cancer.  The observation that DHT has a strong effect on the AR-null 
PC3 (androgen-independent) cell line, implicates a mechanism of DHT action independent 
of AR binding.  Interestingly, DHT presence increased cabazitaxel cellular entry in PC3 
cells, but not in LNCaP cells or PC3-shSLCO1B3 cells.  The complicated relationship 
between androgens and taxane therapy is far from being fully understood, but assisting in 
cabazitaxel cell entry could be advantageous if cabazitaxel were given without ADT being 
present.    
HSET, throughout my studies, was consistently and reliably located in the nucleus.  
However, in PC3 xenograft tumor staining, HSET was present in the cytosol in a minority 
of untreated tumors, and was present in the cytosol in the majority of cabazitaxel-treated 
tumors.  Viewed with confocal microscopy, cabazitaxel treated PC3 cells in vitro had 
cytosolic localization of HSET.  In addition, PC3-CR cells had cytosolic HSET both before 
and after treatment. The cellular localization of HSET could be a contributing factor in 
cabazitaxel response or resistance, and future mechanistic research is necessary to 
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determine the importance of localization and physiological response.  In contrast to PC3 
cells, cabazitaxel treated LNCaP and 22Rv1 cells, both in vitro and in vivo xenograft 
tumors, showed exclusively a nuclear localization of HSET after treatment.  These data 
require further investigation before the cabazitaxel-induced nuclear localization is 
considered to be reliable and repeatable.  It is possible that the reason HSET is responding 
to cabazitaxel differently in PC3 xenografts than in the LNCaP and 22Rv1 xenografts 
(where HSET was exclusively nuclear in localization) is because PC3 cells do not contain 
any androgen receptor.  The AR-HSET interaction discovered in Chapter 2 could have 
more mechanistic consequences in the cell, with AR transport providing a critical role for 
HSET in the nucleus – without AR, HSET could lose a nuclear role.  Further research into 
this hypothesis is necessary.    
Early evidence indicated that DHT or testosterone transport/blocked SLCO1B3 
transporter but more thorough evidence showed the opposite.  Stable SLCO1B3 
knockdown cells showed an increased intracellular concentration of cabazitaxel, indicative 
of knockdown increasing cabazitaxel cellular uptake.  These data indicate that perhaps a 
decreased SLCO1B3 triggers the upregulation of other membrane transporters, resulting in 
increased cabazitaxel uptake.  The complex, novel relationship between DHT and 
SLCO1B3 discovered here is definitively involved because DHT increased cabazitaxel 
uptake only when SLCO1B3 is present at full biological level – shRNA knockdown of 
SLCO1B3 rendered cabazitaxel uptake independent from DHT’s effect.  This integral role 
of SLCO1B3 in cabazitaxel uptake has not been explored before, and it warrants future 
research as to whether DHT is activating the transporter, or causing upregulation of 
SLCO1B3 or other, undiscovered cabazitaxel transporters.  The current state of 
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pharmacologic inhibitors of SLCO family proteins is limiting – there is no available, 
specific inhibitor for SLCO1B3.  If a specific inhibitor for SLCO1B3 is developed, there 
can be a more thorough investigation into cabazitaxel uptake through specific 
SLCO/OATP family proteins.  Targeting this transporter may have tremendous side effects 
in normal surrounding tissue. 
Therapeutic sequencing in in vivo models done in Chapter 2 of my work indicated 
that in androgen dependent models, sequencing ADT and cabazitaxel will potentially lead 
to a better treatment outcome.  Interestingly, this theory was published in a clinical trial 
when my pre-clinical experiments were underway (236).  The FIRSTANA trial, a 
randomized phase III trial, tested the efficacy of giving cabazitaxel instead of docetaxel as 
a first chemotherapy treatment in patients with chemotherapy-naïve mCRPC (236).   The 
majority of these patients had received first generation AR-targeted therapies, with a small 
number having received abiraterone or enzalutamide treatment.  There was no change in 
median overall survival, with cabazitaxel (20mg/m2) having a median survival of 24.5 
months, cabazitaxel (25mg/m2) of 25.2 months, and docetaxel (75 mg/m2) of 24.3 months 
(236).  There was no significant change in overall survival or progression free survival 
comparing either of the two cabazitaxel doses to docetaxel (1st line chemotherapy).  
However, tumor responses (complete or partial response) were higher in patients receiving 
cabazitaxel (25mg/m2) compared to docetaxel (236).   
One major limitation of the FIRSTANA trial was the very few patients that had 
received second generation antiandrogens abiraterone or enzalutamide.  This was a matter 
of timing, as these therapies were just being introduced into the clinic when the FIRSTANA 
trial was beginning (80, 236).  The other very interesting element of this trial is that it was 
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done exclusively on mCRPC patients.  My pre-clinical data aligns with the outcome of 
FIRSTANA, because no change in sequencing therapies was found in advanced, CRPC 
models of prostate cancer.  The therapeutic potential in my pre-clinical data is in androgen 
sensitive models, before CRPC develops.  It would be interesting to perform a clinical trial 
testing cabazitaxel chemotherapy in patients before CRPC or mCRPC develops, in order 
to prevent mCRPC from developing.  This change may be transformative in the treatment 
regime for prostate cancer patients.  The therapeutic potential of preventing mCRPC is 
worthy of testing in clinical trials, and continued pre-clinical studies. Taken together, this 
data is of high translational significance in identifying novel, potentially targetable 
interactions in advanced lethal prostate tumors.   
In the subsequent segment, I wish to discuss the limitations of my dissertation work. 
Firstly, the PC3-CR cell line had detectable DNA of mouse origin, as discussed in Chapter 
3.  The cell line was majority human, with all detectable markers specific for PC3 cells, 
indicating that the human cells were of PC3 prostate cancer origin.  The contamination 
with murine cells is a limitation, experiments with the cell line were halted once the test 
results were received.  The increase in mesenchymal character correlated with increased 
migratory and invasive characteristics.  This effect is well established both within prostate 
cancer and in other cancers (237-239).  The cross-resistance with docetaxel highlights the 
similar mechanisms of action between microtubule targeting agents docetaxel and 
cabazitaxel, emphasizing the similar mechanisms of resistance that are still unknown.  Not 
to be overlooked, the decrease in SLCO1B3 expression in cabazitaxel resistant cells 
spurred further research into SLCO1B3’s role in cabazitaxel treatment, a line of inquiry 
that requires continued research to understand.  As discussed above, the lack of current 
140 
 
 140 
specific pharmacological inhibition of SLCO1B3 is limiting for the breadth of studies than 
can be done at this time, and in the current therapeutic landscape.  If a specific SLCO1B3 
inhibitor is developed, the efficacy can be tested in pre-clinical models as a combination 
therapy with cabazitaxel and/or anti-androgens to re-sensitize resistant models to available 
therapeutics.   
It is readily apparent that a significant amount of my data is immunohistochemical 
staining, and conclusions drawn from stained slides can be done through qualitative or 
quantitative measures.  The majority of staining, such as E-Cadherin, N-Cadherin, 
Vimentin, and Cytokeratin-18 are analyzed through qualitative measures, visually 
determining the strength of the protein expression.  Some markers, such as AR and HSET, 
were quantified by a board certified pathologist and either myself or the principal 
investigator.  An approach that could have been used is quantification through computer 
program, but was decided against due to access to pathologists and possible errors in 
interpretation by computer analysis.   
A limitation both in my work and persistent throughout the prostate cancer research 
field as a whole is limiting cell models.  The standard research in prostate cancer is done 
on a variety of cell lines, each modeling different stages of disease.  How I utilized this 
was LNCaP, the hormone naïve, androgen sensitive cell line represented androgen 
sensitive disease, 22Rv1 cell line modeled castration resistant prostate cancer, and PC3 
represented androgen independent disease.  There are, of course, differences between the 
cell lines aside from just androgen receptor presence or absence.  Each cell line was isolated 
from a different patient with prostate cancer, from different organs of metastasis, have 
different doubling times, and even different karyotypes.  To validate the findings in my 
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dissertation, using more biologically precise models would be prudent.  For example, to 
study AR-v7, instead of using LNCaP (possessing AR) and 22Rv1 (possessing AR, AR-
v7 and other AR variants), the PC3 cell line could be transfected to express AR or AR-v7 
to guarantee that adding AR or AR-v7 is the only difference in the models studied.  As 
noted earlier, this is a weakness in the prostate cancer field as a whole; the disease 
progression is so extreme from benign to metastatic disease that it is only natural that there 
is a wide spread of cell lines to represent disease stages, but the field can strive to be as 
precise as possible in experimentation.    
 A limitation in the pre-clinical xenograft study examining the effect of tumor 
sequencing is the lack of ADT/castration alone treatment group.  Experimental design for 
this study accounted for the plentiful, established literature regarding the effect of 
castrating on LNCaP and 22Rv1 cells (112, 240-242).  The goal of my xenograft 
experiments was to examine the therapeutic efficacy of sequencing ADT and cabazitaxel 
chemotherapy to optimize therapeutic response, a goal that was achieved in androgen 
sensitive LNCaP cells but resulted in no effect in CRPC 22Rv1 cells.  A limitation, which 
can be focused into future studies, is the lack of survival studies done with preclinical 
mouse models to determine if treatment had an effect on overall mouse survival – a study 
that would be particularly interesting for treatment sequencing.    
Future directions derived from my studies are multifaceted at the mechanistic and 
translational level in the context of developing effective strategies to overcome therapeutic 
resistance in prostate cancer patients with lethal disease.  First, the interaction between AR 
and HSET, and potential therapeutic consequences of targeting this interaction needs to be 
explored further.  Studies will need to be completed using the HSET inhibitor CW069 
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(167), examining the efficacy of the inhibitor in prostate cancer cells both in vitro and using 
pre-clinical in vivo models.  Studies have been done with CW069 and docetaxel in 
combination therapy, an avenue that has promise towards re-sensitizing docetaxel resistant 
cells to therapy (149, 168).  Cabazitaxel and CW069 in combination therapy has not been 
studied, and future research in this area should take into account the interaction of AR and 
HSET that is inhibited by cabazitaxel chemotherapy.  A secondary avenue to further 
confirm the interaction between AR and HSET that should be pursued is a crystal or 
computer generated model of the protein-protein interaction.  While the co-
immunoprecipitation studies showed a clear binding, the technique should be confirmed 
with more extensive investigation.  Along the same thread, potential binding of HSET to 
AR variants, particularly AR-v7, should be investigated as a potential therapeutic target in 
advanced disease that is resistant to standard agents.   
 The paradoxical finding of SLCO1B3 knockdown causing increased intracellular 
cabazitaxel concentration warrants further research.  SLCO1B3 is a strictly influx 
transporter (243, 244) so it is not possible that decreased SLCO1B3 level resulted in less 
drug efflux unless there was a concurrent loss of efflux proteins such as ATP-binding 
cassette transporters or multi-drug resistance-associated proteins (ABC, MDR protein 
families, respectively) (245).  One may consider the possibility that stable SLCO1B3 
functional loss knockdown triggered a feedback loop that resulted in upregulation of other 
SLCO family membrane transporters, and these other transporters allowed increased efflux 
of cabazitaxel.  Other SLCO family protein level will be profiled after SLCO1B3 
knockdown for both protein and RNA level, to determine if there is an upregulation of 
other protein family members resulting in increased cabazitaxel entry.  SLCO1B3 plays a 
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role in cabazitaxel resistance, as shown by SLCO1B3 knockdown inducing a modest 
resistance to cabazitaxel, but it is not the only protein involved.  If SLCO1B3 were the only 
cellular uptake protein for cabazitaxel, knockdown would have had a more complete effect, 
and would have conferred a more substantial resistance with SLCO1B3 knockdown.   
 The most epithelial-like PDX tumors also had the highest expression of SLCO1B3. 
The goal of my dissertation work has been to investigate the underlying mechanisms that 
contribute to therapeutic resistance in prostate cancer.  Cabazitaxel remains the only anti-
proliferative chemotherapeutic option as a 2nd line taxane chemotherapy for prostate cancer 
patients with metastatic disease, alongside AR targeting therapies, radiation, and limited 
immunotherapy.  There are currently more than 650 Phase I and II clinical trials, and over 
140 Phase III trials for prostate cancer treatment in the United States alone (246).  There is 
clinical innovation happening through the ongoing clinical trials, but continued 
advancements in basic science research are much needed to provide mechanism-based 
evidence for supporting pre-clinical guidance based studies towards innovative clinical 
applications with potential impact in patients. The findings described in this thesis provide 
novel insights into the molecular and phenotypic characterization of the prostate tumor 
landscape that may potentially drive new therapeutic platforms through identifying novel, 
actionable targets in advanced prostate tumors in patients with lethal disease. Pending and 
future clinical trials in prostate cancer patients with lethal disease will take several years to 
be interpreted, with the overarching goal to have an impact on patients’ survival so that it 
can be increased from a few months to a few years with thoughtful research enhancing our 
understanding of both tumor biology and therapeutic resistance.   
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